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ABSTRACT 
 
CASCADE ANNULATION AND RING-OPENING REACTIONS OF CASTAGNOLI-
CUSHMAN-DERIVED ALLYLIC AND BENZYLIC THIOMORPHOLINONATES 
by 
Abdikani Omar Farah 
June 2018 
Sulfur-containing compounds are prevalent in antibiotics, essential amino acids, bacterial 
RNA, food flavors, and enzymes. The divalent sulfur atom introduces a metabolic liability from 
a drug discovery standpoint. Indeed, it is quite telling that all the top ten best-selling drugs in 
2012 contained sulfur. In this context, there is a growing need for the synthesis of sulfur-
containing compounds in ways that are practical and cost-effective. One approach taken to 
achieve this goal is to employ diversity-oriented synthesis (DOS), which produces diverse 
complex molecules with similar core structures from a common precursor. When a DOS features 
a cascade or domino reaction in the key steps, the process becomes even more cost- and time-
efficient. In this embodiment, a transition metal-free, base-mediated cascade reaction featuring 
methylesterification of allylic thiomorpholinonyl acids and concomitant regioselective 
intramolecular hydroalkylation is described. The method hinges on the in-situ generation of a 
transient [4.1.0] bicycle, which undergoes selective C˗C bond cleavage to afford sulfur-bearing 
cross-conjugated dienes. Post-diversification of this versatile intermediate to other 
pharmaceutically pertinent motifs such as β-enaminoates, 1,1-enediamines, and enethiols is 
investigated. 
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CHAPTER I 
INTRODUCTION
1.1 Significance of N-heterocycles  
Heterocycles are described as rings that contain at least one non-carbon atom, most 
commonly containing nitrogen, oxygen, or sulfur (N, O, S). Heterocycles can range from three 
membered rings to macro-cycles, over 20 membered rings. Heterocycle skeletons make up 13 of 
the top 20 most frequent cyclic motifs employed in pharmaceutical drugs. Nitrogen-containing 
rings (N-heterocycles) dominate this list, accounting for 10 of the top 20 motifs (Figure 1-1).1   
N-heterocycles are prominent in nature making up the essential components such as nucleic and 
amino acids.2  N-heterocycles have a wide range of biological activity in the treatment of disease, 
from pain management to anti-cancer drugs.  The value of N-heterocycles in pharmaceutical 
drugs may be attributed to their amphiprotic character, good oral activity, and their ability to 
hydrogen bond.3  
There are over 600 pharmaceuticals approved by the U.S. Food and Drug Administration 
(FDA) that have a core structure containing nitrogen heterocycles (Figure 1-2).4 N-heterocycles 
are diverse in ring size, aromaticity, number of heteroatoms, and connectivity. Of the top 25 of 
these N-heterocycles, piperidine, pyridine, piperazine, pyrrolidine, thiazines, morpholine, 
thiomorpholine, and bicyclic moieties are the most common. Since the most frequent ring 
present in drugs is benzene, compounds that contain both N-heterocycles and benzene rings may 
have significant biological activity and pharmaceutical relevance.  
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Figure 1-1: Top 20 most frequently used cyclic motifs in FDA pharmaceutical drugs 
It is worth noting that synthetic and medicinal chemists are entrusted with the early stages 
of drug discovery, including design, synthesis, and formulation. With this in mind, many 
scientists focus on areas of organic synthesis that hold the highest importance and greatest 
demand: chemo-, regio-, and stereoselectivity.5 These areas present significant challenges to drug 
discovery and finding efficient methods to solve chemo-, regio-, and stereo-selectivity problems 
to expedite the discovery process. 
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Figure 1-2: Top 25 N-heterocycles in the top 200 drugs of 2014 
 
1.2 Chemoselectivity 
Chemo-selectivity is the ability of a reaction to occur exclusively at one functional group 
in the presence of other reactive functional groups in the molecule.6 Many reactions in organic 
chemistry are chemo-selective as a result of specific reaction conditions, reagents, and the 
differing reactivity of functional groups.7 Uncontrolled chemo-selection may occur in reactions. 
Examples of this include attack at an amide rather than ester, oxidation of allylic alcohols over 
non-allylic, and the reduction of one alkene over another.8 The Luche reduction is an example of 
altered chemo-selectivity, in which sodium borohydride reduces ketones in the presence of an 
aldehyde. This reduction is mediated by cerium tetrachloride. Without it, sodium borohydride 
reduces the more reactive aldehyde.9 Carrying out chemo-selective reactions is critical in 
synthetic chemistry research, especially for total synthesis groups that are attempting to construct 
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complex natural compounds in high yields.10  The effective design of chemo-selective reactions 
will reduce side reactions, increase yield, and minimize waste. The classic solution to chemo-
selective problems is the masking of functional groups that would otherwise outcompete 
reactivity at the desired functional group. 
 
1.3 Regioselectivity  
Regio-selectivity is defined as a preference for the site(s) at which any reaction takes 
place in a molecule.6 Selective formation or breaking of bonds dictated by the location of the 
reacting site could be as simple as the difference between linear and branched constitutional 
isomers of alkenes upon addition to internal or terminal carbon atoms. Regio-selectivity is often 
dictated by the substitution pattern. Many named reactions like alkene hydration and 
halogenation yielding Markovnikov or anti- Markovnikov products are an example of regio-
selectivity.7 The Baeyer-Villiger oxidation regio-selectively cleaves the carbon-carbon bond of 
the more substituted side of ketones and inserts an oxygen. Regio-selectivity is difficult to 
achieve; therefore, a key element to a greater understanding of the process requires careful 
consideration of the substrate of interest and thoughtful selection of reagents.  
 
1.4 Stereoselectivity  
Stereo-selectivity is the most prominent, problematic, and difficult to control of the three 
selectivity factors. Stereochemical configuration depends on a combination of variables, 
including reagents and structure. Stereo-selectivity is where a reaction can form two or more 
products that differ in their three- dimensional orientation, such as the formation of  cis/trans, 
syn/anti, exo/endo, R/S, or L/D stereoisomers.6 
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Since Louis Pasteur first successfully separated the two isomers of sodium ammonium 
tartrate, stereochemistry of compounds has been widely investigated.11 Stereo-selectivity is 
critical both in pharmaceuticals and in nature, often because one of the two isomer forms may be 
more functional, potent, or biologically active over another. Nature itself is selective for isomers, 
such that essential compounds like proteins, amino acids, and sugars often exist as one isomer in 
biological systems.  
Pharmaceutical drugs and biologically active compounds are frequently chiral and often 
possess more than one stereocenter. As the number of chirality centers increases in a molecule, 
the number of possible stereoisomers increases exponentially. Although some reactions are 
inherently stereo-selective, sophisticated chromatographic methods are often required to separate 
stereoisomers. Consequently, obtaining a desired single isomer is often tedious, labor and time 
intensive, and costly. In pharmaceuticals, synthetic organic chemists are entrusted with this 
process; hence, the deliberate design of substrates and reaction conditions that yield the desired 
isomer is paramount to the process of drug discovery.  
In the pharmaceutical industry, the isomeric problem has not been easy to resolve and 
many current drugs are still sold as racemic mixtures. Knowing isomers are different in activity, 
toxicity, and potency, the FDA requires that new drugs must be a single pure enantiomer unless 
the racemates have identical function.12 This policy was enacted following the discovery of the 
devastating side effect of thalidomide (Figure 1-3). Thalidomide was marketed as an (R/S) 
racemic mixture to treat morning sickness in pregnant women (Figure 1-3). It was later 
discovered that the R enantiomer of thalidomide was effective against morning sickness while 
the S enantiomer was toxic and led to birth defects such as deformed limbs and internal organs.13   
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Figure 1-3: Thalidomide R and S enantiomers 
To reiterate the importance of stereochemistry in pharmaceutical drugs, 
methamphetamine is a highly addictive and illegal drug, which targets dopamine receptors to 
release dopamine, causing euphoria, psychosis, and violent behavior. Methamphetamine has two 
optical isomers (R)-(+)-methamphetamine, and (S)-(+)-methamphetamine, also known as L- or 
levo-methamphetamine and D- or dextro-methamphetamine, respectively (Figure 1-4). The L 
isomer is sold as an over the counter nasal decongestant while the D isomer is an illegal 
recreational drug that is sometimes used for enhancing sports performance.14 Most notably Alain 
Baxter, a Scottish Olympic medal winner in skiing, was stripped of his awards after drug testing 
revealed the presence of banned substance D-methamphetamine when he used the nasal 
decongestant. The vast difference in drug activity by the two stereoisomers of methamphetamine 
demonstrates the importance of isolating stereo-isomers.  
 
Figure 1-4: D and L enantiomers of methamphetamine 
1.5 Diversity-oriented synthesis  
Since the successful mapping of the human genome, over three thousand new drug 
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targets have been identified, but the rate of FDA approval of new drugs has decreased. In this 
regard, an immense responsibility falls on synthetic organic and medicinal chemists to discover 
and assemble new lead compounds. Diversity-oriented synthesis (DOS) has become famous for 
its cost-effectiveness and time-saving ability in the early stages of drug discovery programs. 
DOS provides lead molecules with potential to become drugs from cheap and readily available 
scaffolds.15  
An example of the importance of DOS is bupivacaine and structurally related, 
ropivacaine, and mepivacaine that are local anesthetic drugs administered by epidural during a 
woman’s labor (Figure 1-5).16 The substitution of alkyl chains at the amine position give varying 
pKa constants among the similar structures of mepivacaine (pKa = 7.6), ropivacaine (pKa = 7.7), 
and bupivacaine (pKa = 8.1).
17 Interestingly, ropivacaine and mepivacaine are found to be faster 
acting relative to bupivacaine; while, ropivacaine and bupivacaine are longer-lasting than 
mepivacaine. Furthermore, mepivacaine and ropivacaine are less toxic than bupivacaine. 16  A 
modest change on the secondary amine substituent leads to a broad range of differences in 
potency, pharmacokinetics, and toxicity between the three anesthetics.   
 
Figure 1-5: Closely related local anesthetics mepivacaine, ropivacaine, bupivacaine 
Contrary to DOS, scientists utilize target-oriented synthesis (TOS) method to construct 
pre-determined targets by complex generating and fragment coupling reactions, such as Diels 
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Alder.15 TOS relies on the retrosynthetic scheme, while DOS is forward synthesis. DOS and 
TOS complement each other, specially they are used in contingent, DOS is considered a lead 
generating while TOS is said to be lead optimizing in drug discovery programs (Figure 1-6).15   
 
Figure 1-6: Diversity oriented and target oriented synthesis pathways 
The superiority of diversity-oriented over target-oriented synthesis lies the ability of DOS 
to generate a library of structurally diverse compounds, which can be readily examined in high 
throughput screening (HTS) (Figure 1-7). Unlike TOS, the diverse library of compounds 
obtained through DOS can more quickly produce a hit against biologically hard to access targets, 
such as receptors and proteins.18,15 
Antibiotic resistance lies in the ability of bacteria to evolve and mutate its DNA by 
making new enzymes to metabolize the drug or modifying their transmembrane proteins to 
decrease binding efficiency. The DOS library of compounds would conveniently address factors 
that cause bacterial resistance without the arduous and costly invention of a new drug. For 
example, the scaffold of many antibiotics is often the same, (β-lactams antibiotics) and scientists 
have modified the peripherals of the core motif to increase potency and overcome resistance. 19, 
20  These are called second or third generation antibiotics 
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Figure 1-7: DOS route to drug discovery 
1.6 Cascade reaction 
 DOS methodology relies on complexity generating reactions,15 such as cascade, domino, 
and tandem reactions to generate compounds with diverse conformations and configurations.18  
Cascade reaction can be induced by various reagents, including electrophiles, nucleophiles, 
radicals and often transition metals.21 Cascade and domino type reactions have been highly 
sought after recently in part with the desire of the synthetic organic chemistry field to be more 
environmentally conscious. Not only do cascade reactions decrease waste, which would have 
been generated in multi-step processes and promote green chemistry, but they also exceedingly 
step and atom economical. In addition, cascade reactions save time in part with the reduced 
number of reactions, work up and characterization.22 
 
1.7 N-, S-heterocycles  
Nitrogen and sulfur-containing heterocycles are a monumental part of top pharmaceutical 
drugs as can be seen in Njardarson’s collection of top 200 drugs in 2014.4 N-, S-heterocycles 
makeup 4 of the top 10 N-heterocycles, including cepham, thiazole, penam, and phenothiazine 
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(Figure 1-2).4 On the other hand, N-, S-heterocycles are found in the most crucial drugs known to 
man, antibiotics. The prominence of N-, S-heterocycles in pharmaceuticals is due to their ability 
to form disulfide bonds with enzymes, proteins, and cofactors.23 Since the introduction of 
antibiotics, N-S heterocycle has customarily been core motif in pharmaceuticals. Cepham and 
penam contain beta-lactam conjugated 6-member (dihydrothiazine) and 5-membered 
(thiazolidene) rings respectively. Cepham and penam rank 9th and 12th in the top 20 periodically 
used ring structures, and line up 4th and 8th in top 200 nitrogen heterocycles (Figure 1-1 and 1-
2).1,4 The alarming rate of resistance against antibiotics by infectious microorganisms is paving 
the way for synthetic and medical chemists to innovate new and groundbreaking novel N-, S- 
containing heterocycles.24,25 Phenothiazine is a 6-membered ring with nitrogen and sulfur at 
positions 1 and 4. This motif ranks 10th in the top 200 N-heterocycle drugs.4 
In addition to their fame in antibiotics, N-S six-member heterocycles core motifs in anti-
parasitic disease, antipsychotic, as well as pain management medications drugs (Figure 1-8) 
Cephalosporin 10 is a β-lactam antibiotic used to treat bacterial infections. Since its discovery in 
1945, various R1 and R2 groups have been appended to increase the potency of this drug as 
bacteria develop resistance to generation-one antibiotics.26 Prochlorperazine maleate contains the 
phenothiazine core motif. Upon many of its uses in migraines, dizziness and nausea, it is mainly 
prescribed for antipsychotic purposes due to its potent dopamine receptor antagonist 
function.27,28 Sutezolid is a thiomorpholine containing drug that is used to eradicate 
mycobacterium that causes tuberculosis. Sutezolid was introduced after showing superior 
potency relative to its morpholine analog (linezolid).29,30 Dimetotiazine is another phenothiazine 
skeleton containing drug. Dimetotiazine is an effective serotonin receptor antagonist and is used 
to treat migraines. It also has antidepressant activity.31   
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Figure 1-8: N-S six member heterocycles 
Next, 1,4-thiazines like phenothiazine, 1,4-dihydrothiazines and thiomorpholines are 
abundant in pharmaceuticals and in nature, which amplifies their synthetic demand. Since Landis 
first reported the synthesis of 1,4-thiazines, many have fashioned methods to 1,4-thiazines, such 
as Stirling, utilizing ortho-aminothiophenol and dichloroethane.32 Torroba uses N-
ethyldisopropy- amine and sulfur monochloride.33, 34 Similarly, Thiomorpholines which can be 
seen as saturated 1,4-thiazine, are well investigated due to their pharmaceutical relevance.  
Closely related motifs of morpholines and thiomorpholines drugs vary in activity, for 
example, sutezolid and linezolid analogs.  Often thiomorpholine motifs are preferred over 
morpholines due to the acidity of thiol groups, which enables them to remain stable in stomach 
acid conditions as well as readily form stable disulfide bonds.35  
 
12 
 
1.8 Synthetic approaches to N-S heterocycles 
Next, Figure 1-9 showcases some of the synthetic approaches to thiomorpholines by the 
likes of Bode, who achieved α-amino aryl thiomorpholine synthesis using stannyl amine protocol 
(SnAP) reagents and aldehydes.36  Utilizing Castagnoli and Cushman three-component reaction, 
Krasavin attained substituted thiomorpholine from thiodiglycolic anhydride and imine.37  In 
addition, Carreira used Lewis acid catalyzed aminal from 3-oxetanone ring expansion and thio-
ether to furnish subistited thiomorpholines.38 and Garcıa-Valverde constructed thiomorpholines 
utilizing three component Ugi reaction.39 Similarly, Aggarwal produced thiomorpholines using 
annulation reactions of β-heteroatom amines with vinyl sulfonium salts.40 
 
Figure 1-9: Some of the synthetic approaches to thiomorpholines 
  The α-oxy and alpha-sulfide hydrogen in morpholines and thiomorpholines are much 
different in acidity. The thiomorpholine C2 proton is more acidic due to the larger size of the 
sulfur atom (Figure 1-10).  To put in a numerical perspective, studies show the gas-phase 
acidities of morpholine and thiomorpholine C2-H (equatorial) are 1677.8 kJ/mol and 1608.7 
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kJ/mol respectively.41 This being the free energy change of the deprotonations: the lower value 
corresponding higher acidity.  This enhanced acidity is attributed to thiomorpholine vulnerability 
to ring openings which makes the synthesis of thiomorpholines labor intensive and 
problematic.42  
 
Figure 1-10: Morpholine and thiomorpholine structures 
 
Another difficulty associated with thiomorpholines is benchtop stability which abrogates 
any further manipulation and late-stage functionalization. In addition to these drawbacks, side 
reactions, undesirable enantiomeric and diastereomeric ratios, as well as low yields, drive away 
synthetic groups from perusing thiomorpholine research. Thus, reducing the pool of multi-
substituted thiomorpholine motifs available for drug discovery programs. The virtue of 
thiomorpholines lies in the ability to serve as bridge and backbone in complex motifs, as well as 
functionalizing the sulfide group, unlike morpholines. The simplest example, being the oxidation 
of the sulfide to sulfone, which drastically increases the solubility in the body of drugs.  
 
1.9 Statement of purpose 
The goals of this thesis were to study the following.  
• Heteroatom and solvent dictated addition of alkenyl Grignard reagents to (thio) 
morpholinonates 
• Base-mediated intramolecular hydroalkylation of allylic thiomorpholinonates for the 
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synthesis of cross-conjugated N-aryl-1,3-diene 
• Tandem annulation and amine-assisted hydro-alkylation of allylic 
chlorodihydrothiomorpholinates 
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CHAPTER II 
HETEROATOM AND SOLVENT DICTATED ADDITION OF ALKENYL GRIGNARD 
REAGENTS TO (THIO)MORPHOLINONATES 
 
2.1 Introduction   
The biological relevance of N-, O- and S-heterocycles, their frequent use as chiral 
auxiliaries and ligands, as well as their architectural complexity make them extremely attractive 
to the medicinal and synthesis communities. This inspired the development of more flexible, 
cutting-edge, time-honored, environmentally benign and step-economical methods, to construct 
peripheral functionalization compounds which then could be evaluated their structure-activity 
relationships (i.e., SAR).43 
Employing diversity-oriented synthesis, we recognized the merits of the Castagnoli-
Cushman approach (e.g., the use of cheap and easy to make chemicals such as amines, aldehydes 
and cyclic anhydrides to readily access non-flattened sp3-enriched core structures with two 
vicinal stereocenters). Our group has determined mild and robust reaction conditions to give an 
ideal balance of reactivity and selectivity to attain cycloadduct 3.44 Through careful mitigation of 
the α-CH acidity of cyclic anhydrides of type 2a-d (Fig 2-1), and through rational design of 
inherently promiscuous 1,3-azadienes such as 1,45 the synthetic utility of 3 was amply 
demonstrated. First, chemoselective functionalization of 3 with organometallic reagents provided 
expedient access to allylic lactamoyl alcohols such as 4, which themselves served as synthetic 
intermediates for accessing lactam-fused dihydropyrans of type 5b and pentannulated lactams 
such as 5a.45 In addition the epoxidation of allylic lactomyl ester 3 resulted in four consecutive 
stereocenters 6.  
16 
 
 
 
Figure 2-11: Versatile utility of synthetic intermediate lactamoyl ester 3 
Morpholines and thiomorpholines are nitrogen-containing six-membered heterocycles 
that differ only by a single atom. Oxygen and sulfur are in the same group of the periodic table. 
Sulfur has a significantly larger atomic radius, while oxygen is much more electronegative. The 
differences in size and electronegativity lead to dissimilar physical and chemical behaviors. For 
example, thiols are stronger acids than alcohols, but alcohols are much stronger hydrogen bond 
donors.46  The most common synthetic approaches to morpholines and thiomorpholines are 
similar, often interchanging sulfur and oxygen in the starting material.36, 38, 37, 40 Similarly, 
through Castagnoli-Cushman reaction and subsequent methylation, our group has constructed a 
library of vicinally functionalized morpholinonate and thiomorpholinonates.  
Previously we have demonstrated that the addition of aryl, alkyl, allyl and alkynyl 
Grignard reagents to lactamoyl ester 3 through furnishes synthetically versatile tertiary alcohol 4 
(Fig 2-1).45 Recognizing the synthetic potential of the lactamoyl ester 3 as well as organometallic 
reaction tertiary alcohol products 4, we endeavored to further evaluate the scope of alkenyl 
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Grignard reagents when added to lactamoyl esters, especially morpholinonates (Figure 2-2). 
 
Figure 12-2: Competing 1,2 and 1,4 addition products of vinyl magnesium bromide addition to 
morpholinonates  
We recognized the challenges that belie the transformation such as achieving selectivity 
between the competing 1,2- and 1,4-addition reactions. Our concern about selectivity is built on 
the known chemoselective challenges of addition of alkenyl Grignard reagents to methyl esters. 
For example, Lubell has observed the formation of 1,4-addition product 13b as a minor product 
in the presence of the major 1,2-addition product 13a during the direct addition of excess 
vinylmagnesium bromide to methyl ester 11 (Figure 2-3A).47 As expected, Lubell used copper-
mediated conditions to bias the selectivity toward formation of the 1,4 addition product. In 
addition to the regioselective challenge, we are also faced with a chemoselective problem given 
that electronically suitable δ-valerolactams of type 14 are known to react with excess alkenyl 
Grignard reagents such as 15 to afford β-aminoketones of type 16.48 
 
Figure 2-3: Inherent challenges associated with the addition of alkenyl Grignard reagents to 
esters and lactams 
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Our precursor (i.e., 7) contains lactam, ester, and alkenyl groups, which have the 
propensity to react with alkenyl Grignard reagents.49 The latter mode of reactivity is often 
referred to as carbomagnesiation of alkenes. In addition, trials and tribulations of organometallic 
reactions are well documented.50 Therefore, careful experimental setup, as well as intelligent 
design of reaction conditions are desirable. 
Moreover, in the event that we successfully obtain the homoallylic ketone, we envision 
utilizing it to access highly sought after bicycles such as 19, 21, and 24 (Fig. 2-4).  
 
Figure 2-4: Potential synthetic utility of homoallylic ketones 
The homoallylic ketone motif is very pronounced in the synthetic community as this 
motif holds two key important synthetic intermediates, a carbonyl and an alkene.51 In addition, γ, 
δ-unsaturated carbonyl motifs are widely used for the synthesis of a range of heterocycles such 
as cyclic peroxides and oxabicyclooctanes.47  Thus, it is not a surprise that their construction is 
highly sought after, leading to numerous publications. Nevertheless, there is still an ongoing 
demand for the development of soft reaction conditions that are cost-effective. Figure 2-5 
displays some of the synthetic approaches to homoallylic ketones, including ruthenium-catalyzed 
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acetylene reactions with allyl alcohols (Fig. 2.5A),52 Claisen-type [3,3] sigmatropic 
rearrangement of ally vinyl ether (Fig. 2.5B).53 Additionally, Aponich et al utilized gold (I) in a 
reaction of allylic alcohol and alkynes and concomitant Claisen rearrangement to yield γ,δ-
unsaturated ketones (Fig. 2.5C),54 In contrast, Paquin achieved the construction of homoallylic 
ketones via allylation of fluorinated silyl enol ethers under palladium catalysis (Fig. 2.5D).55 In 
spite of these success stories, the use of harsh reaction conditions and costly transition metals 
makes these approached less appealing. Certainly, atom-economical, time-efficient, and labor-
unintensive methods to achieving selectivity are much needed.  
  Figure 2-5: Synthetic approaches to homoallylic ketones 
2.2 Results and discussion 
Grignard reagents are versatile nucleophiles widely used in reactions featuring various 
electrophiles such as ketones, ester, amides, epoxides and more.56 Our initial step toward 
developing a method that would allow us to access homoallylic ketones was to evaluate various 
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solvents in hopes of finding regiodivergent pathways to 1,4 addition and 1,2 addition products. 
As depicted in (Figure 2-6), we screened four solvents; tetrahydrofuran (THF), 2-methyl 
tetrahydrofuran (2-MeTHF), diethyl ether (Et2O) and tert-butyl methyl ether (TBME). We 
determined that more coordinating THF solvent promotes the formation of the 1,2 addition 
product 9a (entry 1&5) whereas the bulkier TBME solvent encouraged the formation of 
homoallylic ketone 10a (entry 4).  
 
Figure 2-6: Reaction solvent optimization studies 
2.2.1 Synthesis of bis-allylic tertiary alcohols  
After careful deliberation of Figure 2-6 results, we proceeded to construct bis-allylic 
tertiary alcohols type 9a. Addition of alkenyl Grignard reagents to various morpholinonates with 
varying N-substituents were examined. Adding excess vinyl magnesium bromide the 
morpholinonate gave morpholinols as 1,2 addition products (Figure 2-7). N-tert-butyl 9a, 9b, 
cyclopropyl 9c, and isopropyl 9d, 9f lead to the same morpholinol products. In addition, aryl and 
benzyl substituents also gave the same results 9e and 9g respectively. The reactions also 
proceeded with the various a-amino groups such as p-methoxy phenyl and disubstituted alkene.  
21 
 
 
 
Figure 2-7: Allylic morpholinols from 1, 2-addition of alkenyl Grignard reagents 
 
Next, a library of morpholinonate compounds were tested to examine if this reaction 
pathway is taken by other alkenyl Grignard reagents specially substituted alkenyl reagents. 
Isopropenyl magnesium bromide readily reacted with the allylic morpholinoates to yield the bis-
allylic tertiary alcohols 9h-j. 2-methyl-1-propenyl magnesium bromide gave similar result 9k. In 
addition to readily reacting with allylic morpholinonates, the great modularity of alkenyl 
Grignard reagents is apparent when benzylic morpholinonates equally furnish morpholinol 9l. 
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Figure 2-8: Isopropenyl and 2-methyl-1-propenyl magnesium bromide derived allylic 
morpholinols 
However, 2-methyl-1-propenyl magnesium bromide and its constitutional isomer 1-
methyl-1-propenyl magnesium bromide gave unalike products. While 2-methyl-1-propenyl 
magnesium bromide gave the bis-allylic tertiary alcohol, reaction with 1-methyl-1-propenyl 
magnesium bromide did not provide 9m.  This indicated that external geminal substitution is 
allowed while vicinal substitution is not allowed due to crowding of the four methyl substituents, 
which sterically hinder attack on the ester.  
 
Figure 2-9: Sterically hindered allylic and benzylic morpholinols 
The synthetic utility of this bis-allylic morpholinol is boundless. For example, Nazarov 
type reaction would produce another ring in the motif,57 or direct oxidation o the tertiary allylic 
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alcohol.58 
 
2.2.2 Bis-homoallylic ketone synthesis 
 
Given the merits of homoallylic ketones, we sought to construct a library of homoallylic 
ketone containing heterocycle motifs from the addition of alkenyl Grignard reagents in tertbutyl 
methyl ether with various N-substituted and allylic and benzylic morpholinonates. N-alkyl and 
aryl substituents both proceed with excellent diastereomer ratios. Reaction with N-isopropyl 10a, 
10b gave better diastereomer ratio than N-cyclopropyl 10c. In addition, N-aryl 10d, 10e which 
bear styrenyl and phenyl substituents on α-amino give similar yields.  
 
Figure 2-10: 1, 4-addition derived lactamoyl bis-homoallylic ketones 
This reaction has proven to be facile and flexible by not only producing bis-homoallylic 
ketone but high to excellent diastereomer ratios. We envision the addition of excess 2-methyl-1-
propenyl magnesium bromide to the morpholinonates would furnish a new stereocenter when the 
reaction proceeds through 1,4 addition. The construction of a new stereocenter α to the carbonyl 
group with complete control is remarkable (Figure 2-11).  
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Figure 2-11: Lactamoyl bis-homoallylic ketone with three stereocenters 
  Although the absolute configuration of the new stereo-center has yet to be 
determined, the exceptionally high diastereomer ratio observed in this motif containing three 
stereocenters is a phenomenon of its own. Various N-substituents such as tert-butyl 10a-j, 
isopropyl 10k, and cyclopentyl 10i all produce the desired product (Fig 2-11). In addition to N-
substituents, we varied the α-amino substituents, styrenyl groups afford bis-homoallylic ketone 
while phenyl, thiophene, and 4-methoxy phenyl produce the same results without diminishing 
the yield.  
 
2.2.3 Addition of alkenyl Grignard reagents to thiomorpholinonates  
Furthermore, we attempted to extend this copper free addition of alkenyl Grignard 
reagents method to thiomorpholinonates. However, we were disappointed by the isolation of ring 
opened and homologated products 41 and 42. Further investigation of this cases will be 
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conducted by future students in the Beng Research Group. 
 
Figure 2-12: Addition of vinyl magnesium bromide to a thiomorpholinonate 
Admittedly, this particular reaction epitomizes the frustration researchers deal with. 
Details about this transformation will be disclosed in the future investigations.  
 
2.2.4 Proposed Mechanism 
We theorize the morpholine reaction mechanism proceeds through the addition of alkenyl 
Grignard reagent 8 to the carbonyl of the morpholinonate 7 to give a rise to a tetrahedral 
intermediate 43, followed by the elimination of the methoxy of the ester to furnish enone 
intermediate 44. The addition site of the second vinyl magnesium bromide is dictated by the 
solvent. More coordinating and less bulky THF promotes the addition of the second Grignard 
reagent to the ketone to give tetrahedral intermediate 45. Tertiary alcohol is then obtained 
through an aqueous work up. On the other hand, the bulkier TBME solvent is believed to hinder 
attack on the ketone by the second Grignard reagent which leads to the addition of the Grignard 
reagent to the less hindered alkene to give intermediate 46.  An aqueous work up gives bis-
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homoallylic ketone 10a. 
 
Figure 2-13: Proposed mechanism 
 
 
2.3 Conclusion 
 Herein, we have achieved solvent-controlled, direct copper-free addition of alkenyl 
Grignard reagents to vicinal functionalized morpholinonates. In addition, we were able to regio-, 
chemo-, and stereo-selectively synthesize morpholine-bearing, doubly-branched homoallylic 
ketones. The operationally simple, scalable, step-economical, transition metal-free, 
stereoselective and high-yielding natures of the transformation bode well for future late-stage 
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assembly of complex pharmaceutically pertinent morpholines. We attempted to extend of 
methodology to thiomorpholinonates and ended up exposing their incessant ring-opening nature.  
 
2.4 Methods 
 All experiments involving air and moisture sensitive reagents such as palladium 
precatalysts and organolithium reagents were carried out under an inert atmosphere of nitrogen 
and using freshly distilled solvents. Column chromatography was performed on silica gel (230-
400 mesh). Thin-layer chromatography (TLC) was performed using Silicycle SiliaplateTM glass 
backed plates (250 µm thickness, 60 Å porosity, F-254 indicator) and visualized using UV (254 
nm) or CAM, p-anisaldehyde, or KMnO4 stain. Unless otherwise indicated, 
1H, 13C, and DEPT-
135 NMR, COSY 45, HMQC, and NOESY spectra were acquired using DMSO-d6 or CDCl3 as 
solvent at room temperature. Chemical shifts are quoted in parts per million (ppm).  
2.4.1 General procedure A: synthesis of cyclic thiodiglycolic anhydride  
To a round-bottom flask, 2-2 thiodiacetic acid (1.5015g, 10 mmol), (trifluoroacetic 
anhydride 3.10ml, 2.2 equivalents) and (dry 60ml of ethyl acetate) was stirred in room 
temperature for 2 days. The resulting solution was rotovaped and washed with petroleum ether 
(3X 10ml) 
Diglycolic anhydride (116.07) was purchased from Sigma Aldrich.  
2.4.2 General Procedure B: Synthesis of 1,3-azadienes 
To a round-bottom flask equipped with a stir bar was added the enal (10 mmol), amine (1 
to 1.5 equiv), benzene (50 mL), and anhydrous MgSO4 (2 g). The cloudy suspension was 
allowed to stir at room temperature. After complete consumption of the amine (based on TLC 
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monitoring), the mixture was filtered through and concentrated under reduced pressure to obtain 
the crude enamine, which was used in the next step without further purification. 
Note: The azadienes need to be stored in the refrigerator when not used immediately. 
2.4.3 General Procedure C: Reaction of 1,3-azadienes with cyclic 
anhydrides 
A 5 mL screw-cap vial was flame-dried, evacuated and flushed with nitrogen. A solution 
of the 1,3-azadiene (1.0 mL, 0.10 M in freshly distilled toluene) was added to the vial at room 
temperature followed by the cyclic anhydride (1 to 1.1 equiv). The contents were placed in a pre-
heated oil bath thermostatted at the desired temperature (e.g., 90 oC for diglycolic anhydride). 
After complete consumption of the enal (as judged by TLC and NMR), the mixture/suspension 
was cooled to room temperature and washed several times with petroleum ether, then 
concentrated under reduced pressure to afford the crude cycloadducts. 
2.4.4 General Procedure D: Methyl esterification of cycloadducts 
To a stirring suspension of the acid (1 mmol), dissolved in DMF (5 mL), and K2CO3 (6 
equiv) was added methyl iodide (3 equiv) under nitrogen atmosphere. The reaction mixture was 
stirred for 12 to 18 h (TLC monitoring). After complete conversion, it was diluted with water and 
extracted with EtOAc (2×20 mL). The combined organic extracts were washed with brine, dried 
over Na2SO4 and concentrated in vacuo to give the desired ester. 
2.4.5 General procedure E: Addition of alkenyl Grignard reagents to 
morpholinonates and thiomorpholinonates 
To the lactamoyl ester (1.0 mmol) dissolved in freshly distilled THF (5 mL), was slowly 
added vinylmagnesium bromide (3.0 mL, 1.0 M solution in THF, 3 equiv) under nitrogen at ‒
78 °C. The mixture was warmed slowly to room temperature. After complete consumption of the 
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ester (as indicated by TLC and GC-MS), the mixture was cooled to 0 °C, diluted with Et2O and 
quenched by slow addition of sat. aq NH4Cl. The layers were separated and the aqueous layer 
was extracted twice with EtOAc. The combined organic layers were dried over Mg2SO4 for 30 
min, filtered, and concentrated under reduced pressure to give the desired product. Purification: 
Flash chromatography on silica (often pretreated with 1% Et3N) eluting with Hexane/EtOAc. 
  
2.5 Peak assignments 
2.5.1 Peak assignment for 9a 
 
Prepared using general procedure D in 1 mmol scale. Yield= 90%, 99:1 dr. 1H NMR (400 
MHz, Chloroform-d) δ 7.33 – 7.26 (m, 5H), 6.44 (d, J = 15.9 Hz, 1H), 6.14 – 5.96 (m, 3H), 
5.51 (d, J = 17.2 Hz, 1H), 5.44 (d, J = 17.3 Hz, 1H), 5.29 (t, J = 11.9 Hz, 2H), 4.72 (d, J = 7.6 
Hz, 1H), 4.22 – 4.06 (m, 1H), 3.98 (d, J = 15.4 Hz, 1H), 3.74 (s, 1H), 2.65 (s, 1H), 1.47 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ 170.65, 139.25, 136.09, 131.97, 131.25, 128.78, 128.13, 
127.87, 126.47, 115.20, 115.04, 82.94, 78.32, 67.85, 58.19, 53.32, 28.04. HRMS calc for 
C21H27NO3 341.1991, found 341.1997. FTIR (KBr): 3384.5506, 2924.8333, 1642.2515, 
1494.9545, 1448.8548, 1427.0419, 1393.4602 1361.6968, 1328.7144, 1289.7737, 1223.6425, 
1198.9141, 1130.0001, 1074.1578, 1030.4745, 988.561, 966.1662, 925.5022, 741.6755, 
693.4562. 
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2.5.2 Peak assignment for 9b 
 
Prepared using general procedure D in 1 mmol scale. Yield = 323 mg, 87%. 95:5 dr. 1H 
NMR (400 MHz, Chloroform-d) δ 7.27 (d, J = 8.5 Hz, 2H), 6.85 (d, J = 8.1 Hz, 2H), 6.37 (d, J 
= 15.9 Hz, 1H), 6.13 – 5.88 (m, 3H), 5.51 (d, J = 17.2 Hz, 1H), 5.42 (d, J = 17.4 Hz, 1H), 5.35 – 
5.16 (m, 2H), 4.68 (d, J = 8.0 Hz, 1H), 4.17 (d, J = 15.3 Hz, 1H), 4.06 – 3.93 (m, 1H), 3.80 (s, 
3H), 3.76 – 3.71 (m, 1H), 2.37 (s, 1H), 1.45 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 171.08, 
159.65, 140.67, 130.75, 129.64, 128.79, 127.94, 127.67, 116.62, 115.18, 114.13, 85.22, 78.40, 
67.87, 58.13, 55.41, 53.26, 28.02. HRMS calc for C22H29NO4 371.2097, found 371.2094.  
 
2.5.3 Peak assignment for 9c 
 
Prepared using general procedure D in 1 mmol scale. Yield=291 mg, 82%, 85:15 dr. 1H 
NMR (400 MHz, Chloroform-d) δ 7.29 (d, J = 8.3 Hz, 2H), 6.86 (d, J = 8.2 Hz, 2H), 6.44 (d, J = 
15.8 Hz, 1H), 6.09 – 5.79 (m, 3H), 5.42 (dd, J = 20.0, 17.2 Hz, 2H), 5.23 (d, J = 10.6 Hz, 2H), 
4.27 (dd, J = 15.2, 8.9 Hz, 2H), 4.22 – 4.06 (m, 1H), 3.80 (s, 3H), 3.61 (d, J = 6.1 Hz, 1H), 2.49 
(dq, J = 7.0, 3.5 Hz, 1H), 1.00 (dt, J = 13.2, 6.4 Hz, 1H), 0.81 (dd, J = 10.4, 4.9 Hz, 1H), 0.63 
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(tq, J = 10.1, 5.8, 5.2 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 170.52, 168.42, 159.80, 139.48, 
139.29, 138.88, 138.54, 133.60, 132.35, 129.65, 129.01, 128.70, 127.89, 127.81, 125.47, 122.29, 
115.29, 114.98, 114.95, 114.21, 114.17, 82.25, 81.74, 77.53, 77.45, 77.13, 76.81, 76.12, 68.59, 
67.75, 60.46, 60.14, 58.55, 55.40, 29.75, 28.58, 27.49, 21.11, 14.26, 9.41, 9.07, 8.64, 5.74, 5.17. 
HRMS calc for C21H27NO4 355.1784, found 355.1789. FTIR (KBr): 3384.3862, 3009.7533, 
2933.6078, 1647.735, 1607.2444, 1577.183, 1512.0128, 1454.2907, 1427.6278, 1359.8311, 
1299.2028, 1250.9581, 1176.0437, 1151.5694, 1119.6948, 1031.3279, 990.3239, 927.8622, 
825.4347, 765.0418, 749.7978 
 
2.5.4 Peak assignment for 9d 
 
Prepared using general procedure D in 1 mmol scale. Yield=311 mg, 87% 95:5 dr. 1H 
NMR (400 MHz, Chloroform-d) δ 7.28 (d, J = 8.4 Hz, 2H), 6.85 (d, J = 8.1 Hz, 2H), 6.38 (d, J 
= 15.9 Hz, 1H), 6.06 (dd, J = 17.3, 10.9 Hz, 1H), 6.01 – 5.89 (m, 2H), 5.47 (d, J = 17.2 Hz, 1H), 
5.39 (d, J = 17.3 Hz, 1H), 5.25 (d, J = 11.8 Hz, 2H), 4.36 – 4.18 (m, 3H), 4.02 (d, J = 15.8 Hz, 
1H), 3.79 (s, 3H), 3.66 (d, J = 3.9 Hz, 1H), 2.60 (s, 1H), 1.25 (two d, J = 7.0 Hz, 6H). 13C NMR 
(101 MHz, CDCl3) δ 168.08, 159.70, 139.58, 132.39, 129.06, 128.77, 128.21, 127.89, 115.33, 
114.82, 114.20, 82.88, 78.33, 66.97, 56.35, 55.38, 47.91, 19.99, 19.72. HRMS calc for 
C21H27NO4 357.1940, found 357.1945. 
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2.5.5 Peak assignment for 9e 
 
Prepared using general procedure D in 1 mmol scale. Yield=335 mg, 86%, 95:5%. 1H 
NMR (400 MHz, Chloroform-d) δ 7.36 – 7.20 (m, 10H), 6.28 (s, 1H), 6.00 (dd, J = 17.3, 10.5 
Hz, 1H), 5.85 (dd, J = 17.2, 10.7 Hz, 1H), 5.48 (d, J = 14.6 Hz, 1H), 5.37 – 5.07 (m, 4H), 4.51 
(d, J = 16.4 Hz, 1H), 4.39 – 4.24 (m, 2H), 3.76 – 3.64 (m, 2H), 2.42 (s, 1H), 1.82 (s, 3H). 13C 
NMR (101 MHz, CDCl3) δ 168.09, 138.72, 138.48, 136.55, 136.35, 134.28, 131.78, 129.02, 
128.96, 128.95, 128.86, 128.75, 128.62, 128.49, 128.39, 128.33, 127.79, 127.69, 127.48, 127.30, 
115.26, 78.91, 65.67, 62.11, 45.98, 13.90. HRMS calc for C25H27NO3 389.1991, found 389.1994. 
FTIR (KBr): 389.1994. 3391.272, 3060.2295, 3027.4261, 2924.038, 1724.2643, 1646.3958, 
1494.2931, 1474.3358, 1452.8606, 1432.4058, 1361.9422, 1342.0932, 265.3056, 1205.6142, 
1140.2378, 1071.7973, 1028.3461, 996.4523, 924.2151, 735.4288, 700.2396 
 
2.5.6 Peak assignment for 9f 
 
Prepared using general procedure D in 1 mmol scale. Yield = 276 mg, 81%, 95:5 dr.1H 
NMR (400 MHz, Chloroform-d) δ 7.35 – 7.25 (m, 5H), 6.43 (s, 1H), 6.11 (dd, J = 17.2, 10.7 
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Hz, 1H), 6.00 (dd, J = 17.3, 10.6 Hz, 1H), 5.50 (d, J = 17.2 Hz, 1H), 5.41 (d, J = 17.4 Hz, 1H), 
5.29 (dd, J = 15.1, 10.8 Hz, 2H), 4.45 – 4.23 (m, 2H), 4.22 (d, J = 3.2 Hz, 1H), 4.10 (d, J = 16.2 
Hz, 1H), 3.69 (d, J = 3.3 Hz, 1H), 2.37 (s, 1H), 1.89 (s, 3H), 1.34 – 1.16 (m, 6H). 13C NMR (101 
MHz, CDCl3) δ 168.05, 139.70, 139.34, 137.58, 136.94, 129.69, 128.90, 128.36, 128.29, 
127.04, 115.23, 114.90, 79.16, 66.16, 59.99, 48.62, 19.90, 19.63, 14.57. HRMS calc for 
C21H27NO3 341.1991, found 341.1997. FTIR (KBr): 3384.5368, 2972.9933, 2932.8937, 
1638.2038, 1449.1308, 1364.7192, 1290.2159, 1270.3054, 1247.8533, 1206.5967, 1179.918, 
1131.1074, 1071.4274, 994.4373, 924.8386, 881.7598, 797.4882, 700.0535 
 
2.5.7 Peak assignment for 9g 
 
Prepared using general procedure D in 1 mmol scale. Yield = 309 mg, 81%, 95:5 dr 79%, 
95:5 dr. 1H NMR (400 MHz, Chloroform-d) δ 7.41 – 7.35 (m, 5H), 7.17 (d, J = 8.4 Hz, 2H), 6.86 
(d, J = 8.4 Hz, 2H), 6.37 – 6.28 (m, 4H), 5.44 (dd, J = 21.0, 17.2 Hz, 2H), 5.26 (dd, J = 10.8, 6.5 
Hz, 2H), 4.49 (dd, J = 16.6, 5.2 Hz, 2H), 4.26 (d, J = 16.2 Hz, 1H), 3.90 – 3.73 (m, 14H),  2.72 
(s, 1H). 13C NMR (101 MHz, CDCl3) δ 169.68, 158.55, 139.35, 135.99, 133.82, 132.76, 128.80, 
128.69, 128.14, 127.73, 126.69, 124.71, 115.63, 114.70, 114.20, 83.62, 78.04, 65.55, 60.95, 
55.55. HRMS calc for C24H25NO4 391.1784, found 391.1787. 
 
2.5.8 Peak assignment for 9h 
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Prepared using general procedure D in 1 mmol scale. Yield =295mg, 77% 95:5 dr. 1H 
NMR (400 MHz, Chloroform-d) δ 7.34 (t, J = 7.6 Hz, 2H), 7.21 (t, J = 9.3 Hz, 3H), 6.43 (s, 1H), 
5.43 (s, 1H), 5.18 (d, J = 14.3 Hz, 1H), 5.09 (d, J = 6.8 Hz, 2H), 4.62 (t, J = 5.6 Hz, 1H), 4.24 (d, 
J = 15.9 Hz, 1H), 4.18 – 4.03 (m, 2H), 2.48 (s, 1H), 1.86 (s, 3H), 1.74 (s, 3H), 1.66 (s, 3H), 1.49 
(s, 9H). 13C NMR (101 MHz, CDCl3) δ 171.25, 145.25, 144.09, 138.37, 137.10, 130.06, 129.25, 
128.83, 128.68, 128.59, 128.35, 127.33, 126.99, 114.27, 113.23, 111.95, 83.17, 77.76, 77.44, 
77.13, 76.81, 76.16, 67.82, 65.55, 60.46, 59.31, 58.52, 53.91, 52.67, 28.80, 28.09, 27.73, 21.12, 
20.71, 19.96, 19.11, 14.27, 13.97. HRMS calc for C24H33NO3 383.2460, found 383.2457. FTIR 
(KBr): 3391.475, 2971.495, 2923.9815, 1644.4038, 1491.4705, 1446.8961, 1429.3142 
 
2.5.9 Peak assignment for 9i 
 
Prepared using general procedure D in 1 mmol scale. Yield =314mg, 85% 99:1. 1H NMR 
(400 MHz, Chloroform-d) δ 7.40 – 7.20 (m, 5H), 6.39 (d, J = 15.7 Hz, 1H), 6.08 (dd, J = 15.9, 
8.2 Hz, 1H), 5.27 (s, 1H), 5.17 (s, 1H), 5.12 (s, 1H), 5.04 (s, 1H), 4.76 (d, J = 8.2 Hz, 1H), 4.30 – 
4.25 (m, 1H), 4.21 – 4.08 (m, 1H), 4.01 (d, J = 15.1 Hz, 1H), 2.42 (s, 1H), 1.73 (ss, 6H), 1.47 (s, 
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9H). 13C NMR (101 MHz, CDCl3) δ 171.52, 145.54, 143.95, 136.03, 131.83, 131.42, 128.82, 
127.83, 126.53, 113.82, 113.02, 82.85, 78.26, 68.18, 57.94, 53.82, 28.44, 19.26, 18.87. HRMS 
calc for C23H31NO3 369.2304, found 369.2309. 
 
2.5.10 Peak assignment for 9j 
 
Prepared using general procedure D in 1 mmol scale. Yield =323mg, 81%, 95:5. 1H 
NMR (400 MHz, Chloroform-d) δ 7.27 (d, J = 8.3 Hz, 2H), 6.86 (d, J = 7.8 Hz, 2H), 6.31 (d, J = 
15.4 Hz, 1H), 5.92 (dd, J = 15.9, 8.1 Hz, 1H), 5.25 (s, 1H), 5.16 (s, 1H), 5.11 (s, 1H), 5.02 (d, J = 
8.9 Hz, 1H), 4.72 (d, J = 8.2 Hz, 1H), 4.27 (s, 1H), 4.15 (d, J = 15.2 Hz, 1H), 4.01 (d, J = 15.2 
Hz, 1H), 3.80 (d, J = 3.2 Hz, 3H), 2.43 (s, 1H), 1.67 (ss, 6H), 1.45 (s, 9H). 13C NMR (101 MHz, 
CDCl3) δ 171.59, 159.44, 145.56, 143.37, 131.82, 130.84, 129.49, 128.69, 127.85, 127.65, 
126.54, 114.15, 113.79, 112.02, 82.85, 78.12, 68.28, 68.15, 57.88, 55.40, 53.85, 28.44, 19.08, 
18.43. HRMS calc for C24H33NO4 399.2409, found 399.2411. 
 
2.5.11 Peak assignment for 9k 
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Prepared using general procedure D in 1 mmol scale. Yield = 295 mg, 69%, 95:5 dr. 1H 
NMR (400 MHz, Chloroform-d) δ 7.34 – 7.22 (m, 5H), 6.35 (d, J = 15.9 Hz, 1H), 6.03 (dd, J = 
15.9, 7.8 Hz, 1H), 5.60 (s, 1H), 5.48 (s, 1H), 4.74 (dd, J = 8.0, 2.8 Hz, 1H), 4.15 (t, J = 16.4 Hz, 
1H), 3.95 (d, J = 15.2 Hz, 1H), 3.73 (d, J = 2.7 Hz, 1H), 2.19 (s, 1H), 1.73 – 1.68 (m, 12H), 1.48 
(s, 9H). 13C NMR (101 MHz, CDCl3) δ 171.38, 137.55, 136.24, 135.11, 132.72, 130.79, 129.61, 
128.96, 128.17, 128.04, 128.00, 127.50, 126.60, 84.50, 76.93, 68.27, 57.82, 53.89, 28.88, 26.86, 
25.83, 19.94, 19.72. 
 
2.5.12 Peak assignment for 9m 
 
Prepared using general procedure D in 1 mmol scale. Yield =256mg, 70%, 95:5 dr. 1H 
NMR (400 MHz, Chloroform-d) 7.38 – 7.15 (m, 5H), 6.95 (d, J = 8.4 Hz, 2H),  6.75 (d, J = 8.4 
Hz, 2H), 6.06 (dd, J = 17.2, 10.6 Hz, 1H), 5.88 (dd, J = 17.2, 10.6 Hz, 1H), 5.41 (dd, J = 26.4, 
17.1 Hz, 1H), 5.36 – 5.17 (m, 3H), 5.09 – 4.87 (m, 1H), 4.58 (d, J = 16.2 Hz, 1H), 4.39 (d, J = 
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16.4 Hz, 1H), 3.94 (d, J = 4.5 Hz, 1H), 3.69 (s, 3H),  2.51 (s, 1H). 13C NMR (101 MHz, CDCl3) 
δ 168.09, 158.38, 140.04, 139.48, 139.04, 133.02, 128.93, 128.42, 128.06, 127.98, 127.70, 
127.60, 115.61, 115.19, 114.10, 82.34, 78.51, 66.91, 62.62, 55.36. FTIR (KBr): 3389.6399, 
2934.2038, 1721.2424, 1652.179, 1607.1619, 1511.3616, 1448.8653, 1414.9522, 1341.3255, 
1298.4034, 1245.2497, 1180.2533, 1139.4586, 1075.9955, 1032.9326, 999.444, 926.6047, 
832.0003, 734.9532, 702.6972 
 
 
2.5.13 Peak assignment for 10a 
 
Prepared using general procedure D in 1 mmol scale. Yield =280mg, 82%, 99:1 dr. 1H 
NMR (400 MHz, Chloroform-d) δ 7.35 –7.24 (m, 5H), 6.47 (s, 1H), 5.80 (ddt, J = 16.9, 10.2, 6.6 
Hz, 1H), 5.03 (dd, J = 19.8, 13.5 Hz, 2H), 4.47 (d, J = 7.0 Hz, 2H), 4.38 – 4.27 (m, 2H), 4.27 – 
4.20 (m, 3H), 2.82 (dt, J = 18.0, 7.3 Hz, 1H), 2.64 (dt, J = 17.9, 7.2 Hz, 1H), 2.36 (p, J = 9.3, 8.2 
Hz, 2H), 1.96 (s, 3H), 1.25 (dd, J = 6.3 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 208.40, 165.76, 
136.73, 135.94, 129.41, 128.96, 128.47, 127.36, 115.96, 82.41, 80.85, 65.28, 58.61, 47.66, 38.37, 
29.76, 20.29, 19.71, 15.42. FTIR (KBr): 2976.0754, 2927.2335, 1721.7979, 1650.1792, 
1492.0415, 1438.4625, 1362.2698, 1320.5399, 1290.1484, 1206.364, 1180.3512, 1146.7618, 
1132.397, 995.8166, 918.8793, 700.1334 
 
2.5.14 Peak assignment for 10b 
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Prepared using general procedure D in 1 mmol scale. Yield =282mg, 79%, 95:5 dr.1H 
NMR (400 MHz, Chloroform-d) δ 7.31 (d, J = 8.4 Hz, 2H), 6.87 (d, J = 8.3 Hz, 2H), 6.52 (d, J = 
15.9 Hz, 1H), 6.07 (dd, J = 15.9, 7.8 Hz, 1H), 5.79 (ddt, J = 16.8, 10.2, 6.5 Hz, 1H), 5.02 (dd, J = 
18.6, 13.7 Hz, 2H), 4.58 (dd, J = 7.8, 2.7 Hz, 1H), 4.45 (p, J = 6.7 Hz, 1H), 4.33 (s, 2H), 4.17 (d, 
J = 2.8 Hz, 1H), 3.81 (s, 3H), 2.80 - 2.62 (t, 2H), 2.35 (q, J = 7.0 Hz, 2H), 1.23 (m, 6H). 13C 
NMR (101 MHz, CDCl3) δ 208.27, 165.44, 159.85, 138.71, 132.55,  128.76, 125.36, 115.88, 
114.23, 82.06, 65.73, 55.41, 54.32, 47.40, 38.65, 27.24, 20.43, 19.78. 
 
2.5.15 Peak assignment for 10c 
 
Prepared using general procedure D in 1 mmol scale. Yield =236mg74% 85:15 dr. 1H 
NMR (400 MHz, Chloroform-d) δ 7.31 (d, J = 8.4 Hz, 2H), 6.86 (d, J = 8.4 Hz, 2H), 6.55 (d, J = 
15.8 Hz, 1H), 6.02 –5.77 (m, 2H), 5.05 –4.97 (m, 2H), 4.43 (dd, J = 7.9, 4.5 Hz, 1H), 4.27 (s, 
2H), 3.77 (s, 3H), 3.62 (d, J = 6.1 Hz, 1H), 2.65 – 2.54 (m, 2H), 2.33 (q, J = 7.0 Hz, 2H), 1.00 – 
0.61 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 206.95, 167.86, 159.88, 139.28, 138.83, 136.54, 
133.77, 133.64, 128.47, 127.97, 127.82, 122.82, 115.87, 114.97, 114.20, 82.24, 66.55, 58.37, 
55.40, 38.66, 28.03, 27.19, 9.06, 5.57. FTIR(KBr): 2930.9333, 1721.7229, 1664.1745, 
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1606.8615, 1576.9493, 1511.8758, 1422.3889, 1359.3077, 1300.0014, 1250.9591, 1175.8146, 
1113.165, 1031.2694, 996.2804, 970.248, 923.7263, 826.1509, 764.8959 
 
2.5.16 Peak assignment for 10d 
 
Prepared using general procedure D in 1 mmol scale. Yield =274mg,70% 95:5 dr. 1H 
NMR (400 MHz, Chloroform-d) δ 7.41 – 7.26 (m, 5H), 7.18 (d, J = 8.4 Hz, 2H), 6.88 (d, J = 8.4 
Hz, 2H), 6.38 (d, J = 15.8 Hz, 1H), 6.19 (dd, J = 15.8, 8.3 Hz, 1H), 5.81 (ddd, J = 16.8, 10.1, 5.3 
Hz, 1H), 5.04 (dd, J = 21.7, 13.6 Hz, 2H), 4.78 (dd, J = 8.5, 3.7 Hz, 1H), 4.55 – 4.40 (s, 2H), 
4.31 (d, J = 3.7 Hz, 1H), 3.77 (s, 3H), 2.81 (m, J = 6.8 Hz, 2H), 2.41 (q, J = 7.2 Hz, 2H). 13C 
NMR (101 MHz, CDCl3) δ 207.00, 165.76, 158.86, 136.51, 135.69, 134.82, 132.33, 128.74, 
128.57, 128.45, 126.70, 124.78, 116.01, 114.63, 81.22, 66.27, 61.36, 55.46, 38.80, 21.13. 
FTIR(KBr): 2932.4213, 1721.5204, 1666.3806, 1606.9472, 1511.0233, 1448.5693, 1414.7191, 
1384.979, 1357.4641, 1298.7878, 1247.5543, 1179.3944, 1135.9684, 1031.8974, 995.8644, 
968.9312, 919.9415, 831.0313, 750.2581, 694.7613 
 
2.5.17 Peak assignment for 10e 
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Prepared using general procedure D in 1 mmol scale. Yield =66% 95:5 dr. 1H NMR (400 
MHz, Chloroform-d) δ 7.44 – 7.30 (m, 5H), 7.05 (d, J = 8.4 Hz, 2H), 6.78 (d, J = 8.5 Hz, 2H), 
5.78 (ddt, J = 16.9, 10.3, 6.4 Hz, 1H), 5.25 (d, J = 3.9 Hz, 1H), 5.08 – 4.96 (m, 2H), 4.59 (d, J = 
17.1 Hz, 1H), 4.47 (d, J = 17.0 Hz, 1H), 4.36 (d, J = 3.9 Hz, 1H), 3.72 (s, 3H), 2.77 (dt, J = 18.2, 
7.4 Hz, 1H), 2.66 (dt, J = 18.1, 7.3 Hz, 1H), 2.37 (q, J = 7.4 Hz, 2H). 13C NMR (101 MHz, 
CDCl3) δ 206.79, 165.98, 158.65, 137.56, 136.46, 132.51, 128.92, 128.53, 128.34, 127.60, 
115.98, 114.21, 82.55, 66.34, 62.64 55.39, 38.82, 27.29. FTIR(KBr): 2932.5571, 1721.483, 
1665.4081, 1607.2449, 1511.11, 1431.8598, 1414.7076, 1344.99, 1298.4941, 1245.6515, 
1179.4413, 1135.306, 1031.8607, 996.7789, 921.8434, 832.167, 701.6744 
 
2.5.18 Peak assignment for 10f 
 
Prepared using general procedure D in 1 mmol scale. Yield =324mg, 88% 95:5 dr. 1H 
NMR (400 MHz, Chloroform-d) δ 7.31 – 7.22 (m, 5H), 6.37 (d, J = 15.9 Hz, 1H), 6.08 (dd, J = 
15.9, 7.5 Hz, 1H), 5.39 (s, 1H), 5.16 (s, 1H), 4.57 (d, J = 7.7 Hz, 1H), 4.36 (s, 2H), 4.27 (d, J = 
15.5 Hz, 1H), 4.02 (d, J = 15.4 Hz, 1H), 3.65 (s, 1H), 2.99 (d, J = 16.3 Hz, 1H), 2.76 (d, J = 16.2 
Hz, 1H), 2.18 (s, 3H), 1.78 (s, 3H), 1.46 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 210.43, 169.64, 
145.58, 136.10, 131.84, 131.25, 128.78, 128.13, 126.45, 115.30, 80.22, 67.35, 58.19, 55.05, 
47.16, 32.10, 28.81, 20.17. 
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2.5.19 Peak assignment for 10g 
 
Prepared using general procedure D in 1 mmol scale. Yield =275mg, 80% 87:13 dr. 1H 
NMR (400 MHz, Chloroform-d) δ 7.37 – 7.16 (m, 5H), 5.39 (s, 1H), 5.22 (s, 1H), (s, 1H), 4.52 – 
4.40 (m, 2H), 4.23 (d, J = 14.5 Hz, 1H), 3.52 (s, 1H), 2.94 (d, J = 17.0 Hz, 1H), 2.79 (d, J = 17.1 
Hz, 1H), 2.17 (s, 3H), 1.84 (d, J = 7.1 Hz, 3H), 1.39 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 
210.93, 168.68, 146.60, 143.70, 128.83, 127.21, 126.30, 115.14, 81.11, 66.66, 58.54, 55.32, 
47.59, 32.12, 28.79, 28.09, 18.88. 
 
2.5.20 Peak assignment for 10h 
 
Prepared using general procedure D in 1 mmol scale. Yield =221mg, 83% 95:5 dr.1H 
NMR (400 MHz, Chloroform-d) δ 7.05 (d, J = 8.2 Hz, 2H), 6.89 (d, 8.2 Hz, 2H), 5.38 (s, 1H), 
5.21 (s, 1H), 4.86 (s, 1H), 4.45 (d, J = 16.7 Hz, 2H), 4.21 (t, J = 16.8 Hz, 1H), 3.79 (s, 3H), 3.49 
(s, 1H), 2.95 (d, J = 16.9 Hz, 1H), 2.78 (d, J = 16.8 Hz, 1H), 2.17 (s, 3H), 1.74 (d, J = 7.1 Hz, 
3H), 1.23 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 210.92, 168.43, 158.85, 146.57, 135.66, 
127.88, 127.61, 114.95, 81.00, 66.72, 58.77, 55.39, 54.73, 46.43, 32.13, 29.75, 28.80, 20.35. 
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2.5.21 Peak assignment for 10i 
 
Prepared using general procedure D in 1 mmol scale. Yield =307mg, 88% 95:5 dr. 1H 
NMR (400 MHz, Chloroform-d) δ 7.29 – 7.16 (m, 1H), 6.92 (d, J = 9.5 Hz, 1H), 6.85 – 6.80 (m, 
1H), 5.42 (s, 1H), 5.19 (s, 2H), 4.51 (s, 1H), 4.37 (d, J = 15.7 Hz, 1H), 4.19 (d, J = 15.8 Hz, 1H), 
3.78 (s, 1H), 3.71 (s, 1H), 2.98 (d, J = 16.7 Hz, 1H), 2.76 (d, J = 16.6 Hz, 1H), 2.18 (s, 3H), 1.76 
(s, 3H), 1.32 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 210.69, 168.71, 148.36, 145.78, 128.72, 
126.87, 124.88, 115.31, 81.39, 80.54, 66.97, 58.89, 51.56, 46.67, 32.13, 28.80, 20.21. 
 
2.5.22 Peak assignment for 10j 
 
Prepared using general procedure D in 1 mmol scale. Yield =335mg, 84% 99:1 dr. 1H 
NMR (400 MHz, Chloroform-d) δ 7.27 (d, J = 8.3 Hz, 2H), 6.86 (d, J = 7.8 Hz, 2H), 6.31 (d, J = 
15.4 Hz, 1H), 5.92 (dd, J = 15.9, 8.1 Hz, 1H), 5.25 (s, 1H), 5.16 (s, 1H), 5.11 (s, 1H), 4.72 (d, J = 
8.2 Hz, 1H), 4.27 (s, 2H), 4.15 (d, J = 15.2 Hz, 1H), 4.01 (d, J = 15.2 Hz, 1H), 3.80 (d, J = 3.2 
Hz, 3H), 2.43 (s, 1H), 1.67 (ss, 6H), 1.45 (s, 9H).13C NMR (101 MHz, CDCl3) δ 171.59, 159.44, 
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145.56, 131.82, 129.49, 127.85, 126.54, 114.15, 113.79, 82.85, 68.28, 57.88, 55.40, 
53.85,47.05,32.14, 28.44, 19.08. 
2.5.23 Peak assignment for 10k 
 
Prepared using general procedure D in 1 mmol scale. 1H NMR (400 MHz, Chloroform-d) 
δ 7.25 – 7.14 (m, 2H), 6.96 – 6.83 (m, 2H), 4.95 (dd, J = 12.5, 3.0 Hz, 1H), 4.82 – 4.69 (m, 1H), 
4.71 – 4.60 (m, 1H), 4.48 – 4.28 (m, 2H), 4.27 (d, J = 17.1 Hz, 1H), 4.14 (d, J = 2.7 Hz, 1H), 
3.80 (s, 3H), 3.25 – 3.12 (m, 1H), 2.29 (ddd, J = 13.6, 6.8, 1.1 Hz, 1H), 2.04 – 1.92 (m, 1H), 1.83 
– 1.57 (m, 2H), 1.21 (d, J = 6.8 Hz, 3H), 1.04 (d, J = 6.8 Hz, 3H), 0.94 (d, J = 6.9, 3.3 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 212.21, 165.37, 159.47, 142.36, 131.79, 128.26, 128.15, 114.23, 
82.79, 66.00, 55.34, 54.94, 48.00, 42.69, 39.74, 21.99, 20.06, 19.64, 15.36. 
 
2.5.24 Peak assignment for 10l 
 
Prepared using general procedure D in 1 mmol scale. 1H NMR (400 MHz, Chloroform-d) 
δ 7.22 (d, 2H), 6.85 (d, 2H), 5.00 (d, 1H), 4.97 (dd, J = 8.4, 3.2 Hz, 1H), 4.89 – 4.48 (m, 2H), 
4.47 – 4.34 (m, 1H), 4.38 – 4.22 (m, 2H), 4.27 – 4.15 (m, 1H), 3.81 (s, 3H), 3.18 (dt, J = 7.5, 6.7 
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Hz, 1H), 2.45 – 2.23 (m, 1H), 1.99 (ddd, J = 13.6, 7.7, 1.1 Hz, 1H), 1.77 – 1.34 (m, 11H), 1.05 
(d, J = 6.8 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 212.31, 165.96, 159.46, 142.52, 133.93, 
128.00, 114.32, 113.97, 82.48, 66.24, 57.81, 56.12, 55.31, 42.61, 39.78, 29.75, 28.73, 28.44, 
23.65, 23.50, 16.91. FTIR(KBr): 2965.2971, 2872.3128, 1716.4748, 1650.8904, 1612.9884, 
1585.9456, 1513.1051, 1455.3449, 1359.3702, 1304.1365, 1251.3997, 1177.4761, 1135.5369, 
1033.8548, 996.7497, 896.0777, 833.6912, 804.9269 
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CHAPTER III 
BASE-MEDIATED INTRAMOLECULAR HYDROALKYLATION OF ALLYLIC 
THIOMORPHOLINONATES FOR THE SYNTHESIS OF CROSS-CONJUGATED N-ARYL-
1,3-DIENES AND β-ENAMINOATES 
 
3.1 Introduction 
 Reactions driven by ring-opening of cyclic compounds are common in synthetic organic 
chemistry.59 Frequently, such an approach is used to access other cyclic motifs through a ring-
closing event. However, the acyclic product can sometimes be synthetically and/or medicinally 
more important than the cyclic one.60  Examples of previously reported ring-opening 
transformations to access acyclic compounds include LiBr-assisted deannulation of 
dihydropyrans with thiol nucleophiles (Fig. 3.1a),61 Au-catalyzed ring-opening of dihydrofurans 
(Fig. 3.1b),62 fragmentation of cyclopropanols under palladium catalysis to access functionalized 
enones (Fig. 3.1c),63 Ni-catalyzed vinyl epoxides and aziridine ring openings to access five,- six-, 
or seven-membered cycloalkanes (Fig. 3.1d),64 and photo-induced ring-opening of pyridazines to 
construct nitrogen containing heterocycles (Fig. 3.1e).65 
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Figure 3-13: Examples of metal-catalyzed ring-opening reactions 
Sulfur-containing organic compounds are highly prevalent in natural and various 
biological systems.66–68 The divalent sulfur atom introduces a metabolic liability (prone to 
oxidation, reduction and ring opening)  from a drug discovery standpoint.69 Indeed, it is quite 
telling that all the top ten best-selling drugs in 2012 contained sulfur.70  
Previous work from our laboratories has revealed that base-assisted methyl esterification 
of Castagnoli-Cushman-derived morpholinonyl acid and valerolactamoyl acids of type 9a,b 
proceeds uneventfully to afford esters such as 10a,b.44 In that report, we articulated that 
thiomorpholinonyl acid 11, which harbors a trisubstituted alkenyl motif also undergoes 
successful base-assisted methyl esterification. However, when closely related acid 13, which 
bears a 1,2-disubstituted alkenyl motif was utilized, no allylic thiomorpholinonate was observed. 
GC-MS analysis revealed the presence of a byproduct with an identical molecular weight as that 
of 14. 1H, 13C, and DEPT-135 NMR analyses subsequently revealed the presence of a ring-
opened product of type 14. 
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Figure 3-2: Methylation of N-aryl morpholinonates and thiomorpholinonates 
A close examination of 14 revealed some interesting and synthetically attractive 
structural features. Specifically, 14 contains the β-enamino ester subunit, which is a well-
recognized synthon for accessing azaheterocyclic architectures such as indoles, indolizidines, 
quinolines, pyrazoles, oxazoles, pyridinones, dihydropyridines, tetrahydrobenzoxazines, 
tetrahydrophenanthridines, dibenzodiazepines, aminofuranones.71,72 This versatile motif has also 
been employed as a precursor to 3-aminosugar derivatives and β-amino ketones. Accordingly, 
they are continually sought after by the medicinal community for the synthesis of antitumor, 
antibacterial, anti-inflammatory and anticonvulsant agents. Ring-opened product 14 also harbors 
the N,N-disubstituted-1,3-diene motif, which like Rawal’s diene,73–75  has impacted the arena of 
chemical synthesis beyond imagination.  
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Seeking to construct a diverse library of cross-conjugated dienes such as 14 while gaining 
a full understanding of the mechanistic underpinnings of the ring-opening transformation, we 
embarked on a full investigation of the base-mediated deannulative functionalization of 
Castagnoli-Cushman-derived allylic thiomorpholinonyl acids.  
 
Figure 3-3: Proposed plan for ring-opening of allylic thiomorpholinic acids bearing a 1,2-
disubstituted styrenyl motif or 1,1,2-trisubstituted styrenyl group 
Our heightened interest is supported by the recognition that compounds of type 14 are 
masked surrogates for difficult-to-access N,S-heterocycles and carbocycles such as those 
depicted in Figure 3-4.  
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Figure 3-4: the possible utility of ring open motif 
 
3.2 Results and Discussion 
Ring-opening of S-heterocycles continues to plague the synthesis community owing to 
their thermodynamic instability and the relatively weak carbon-sulfur bond.76 Nevertheless, this 
curse is consistently being turned into a blessing given that a deannulation-annulation sequence 
is commonly employed to synthesize medium to large ring S-heterocycles.77 In this context, an 
approach to highly functionalized thiols, β-enaminoates, and cross-conjugated dienes was 
envisioned whereby a ring-opening event is implicated. 
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As mentioned previously, base-mediated methylation of an internally trisubstituted 
styrenyl thiomorpholinonic acid proceeded without any surprise and yielded the expected ester 
excusively.44 Seeking to establish the generality of the transformation, we commenced these 
studies by subjecting a few other N-aryl-substituted 1,3-azadienes to a Castagnoli-Cushman 
reaction followed by K2CO3-mediated methyl esterification (Scheme 3-1). As a testament to the 
generality of the transformation the corresponding thiomorpholinonates were obtained in good 
yields and without any complications arising from ring-opening. 
 
Figure 3-5: Formation and methyl esterification of internally trisubstituted allylic 
thiomorpholinonates 
 
Remarkably, and congruent with our previous finding, 1,3-azadienes bearing a 1,2-
disubstituted styrenyl motif react satisfactorily with thiodiglycolic anhydride. However, under 
the same reaction conditions methylation of the acid affords the ring-opened isomers depicted in 
Scheme 3-2. Electron-neutral-, rich-, and deficient styrenes are all tolerated in this novel ring-
opening reaction. 
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Figure 3-6: Base-mediated ring-opening of thiomorpholinonates bearing diversely 
functionalized 1,2-disubstituted styrenes 
We have explored the amenability of diverse N-aryl substituents to this deannulation 
protocol. In the event, we find that electron-rich N-aryl lactamoyl acids react with similar 
efficiency as their electron-deficient counterparts (Scheme 3-3, 17e vs 17f). Remarkably, ortho-
substituted aryl moieties can be installed but with a slight decrease in efficiency, which is hardly 
surprising from a steric-encumbrance standpoint. Importantly haloarylated substituents are also 
tolerated, which bodes well for late-stage diversification since the halogen group may be utilized 
as a functional handle for cross coupling purposes. 
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Figure 3-7: Base-mediated ring-opening of thiomorpholinonates bearing diversely 
functionalized N-aryl substituents 
In yet another mechanistically intuitive outcome, these studies have revealed that while 
N-aryl-substituted thiomorpholinic acids bearing internally trisubstituted styrenes are not 
amenable to base-mediated ring-opening (see Scheme 3-1), those harboring an externally 
trisubstituted styrenyl motif are susceptible to incessant ring opening (Scheme 3-4). 
 
Figure 3-8: Base-mediated ring-opening of a allylic thiomorpholinic acid bearing an externally 
trisubstituted styrene 
We have found that this base-mediated ring-opening transformation is very sensitive to 
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the electronic environment of the allylic thiomorpholinic acid. For example, whereas ring 
opening is always observed when inherently more reactive allylic N-aryl-thiomorpholinic acids 
bearing 1,2-disubstituted styrenes are employed, the corresponding N-alkyl-substituted allylic 
thiomorpholinonates are obtained without any fragmentation of the ring (Figure 3-9). The 
synthetic utility of these N-alkyl thiomorpholinonates will be demonstrated in the chapter that 
follows. 
 
Figure 3-9: Base-mediated methylesterification of thiomorpholinic acids bearing diversely 
functionalized N-alkyl substituents 
 
Proposed Mechanism 
On the basis of our observations, it is postulated that this novel stereoselective and 
regioselective ring-opening transformation proceeds through intramolecular hydroalkylation of 
the styrene motif by the in-situ formed ester enolate (Fig. 3-10). The potassium carbonate 
deprotonates the acid 17x to generate the carboxylate ion, which undergoes bimolecular 
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nucleophilic substitution with methyl iodide to afford ester 17y. Enolization of the methyl ester 
at the inherently more acidic α-thioalkoxy/α-acyl position and subsequent intramolecular attack 
of the potassium ester enolate on the styrenyl group delivers transient [4.1.0] bicycle 17w, which 
contains a donor-acceptor cyclopropane. Intermediate 17w is presumably stabilized by the 
benzylic nature of the carbanion. Site-selective cleavage of carbon-carbon bond as well as the 
carbon-sulfur bond can either furnish cross-conjugated diene 17 or its constitutional isomer 17z, 
with complete stereocontrol. Spectroscopic data clearly supports that 17 is the preferentially 
formed isomer. Support for the assertion comes from observation that proton Ha appears furthest 
downfield on 1H NMR spectrum, as expected for an α-amino and sp2-C-H signal. This would not 
be the case if compound 17z were the product of the reaction. 
 
Figure 3-10: Proposed mechanism for intramolecular hydroalkylation of N-aryl-substituted 
allylic thiomorpholinonates 
Intramolecular hydroalkylations of alkenes by ketone enolates, under transition metal-
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catalysis, are well-precedented in literature (Fig. 3-11A/B).78 Of relevance to the current scenario 
is a prior result on intermolecular hydroalkylation of 1,1-disubstituted styrene derivatives using a 
lactam-derived potassium enolate (Fig. 3-11C). In these studies, the authors found that linear 
regioselectivity was favored over branched regioselectivity. In this context, it becomes somewhat 
understandable why in these studies, externally trisubstituted styrenes underwent hydroalkylation 
but the internally trisubstituted ones didn’t. The resonance stabilization accorded by the N-aryl-
substituted lactamoyl acids is critical to formation and stabilization of the transient [4.1.0] 
bicycle given that the N-alkyl variants do not undergo hydroalkylation. 
 
Figure 3-11: Previous reports on hydroalkylation of alkenes 
 
3.3 Conclusions 
The synthesis of thiol-bearing N-aryl-1,3-amino dienes by base-mediated ring-opening of 
allylic thiomorpholinonyl acids, which are readily affordable from 1,3-azadienes and 
thiodiglycolic anhydride through the intermediacy of a Castagnoli-Cushman reaction have been 
accomplished. The protocol is operationally simple and the cross-conjugated dienes are 
obtainable in satisfactory yields and with impeccable regio- and stereocontrol. Detailed 
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mechanistic studies have revealed that the transformation proceeds through an intramolecular 
hydroalkylation pathway, which is extremely sensitive to the stereoelectronic environment. N-
alkyl-substituted acids do not participate in the ring-opening reaction. Externally trisubstituted 
styrenyl groups work well but sterically-encumbered internally trisubstituted styrenes have a 
deleterious effect on the transformation. Significantly, incipient findings from the laboratories of 
our collaborator, Professor Dondji, have revealed that these α-acyl thiols display anti-leishmania 
activity. The synthesis of these Diels-Alder-suitable conjugated dienes bodes well for late-stage 
assembly of azapolycles, details of which will be disclosed in the future. 
3.4 Methods 
All experiments involving air and moisture sensitive reagents such as palladium 
precatalysts and organolithium reagents were carried out under an inert atmosphere of nitrogen 
and using freshly distilled solvents. Column chromatography was performed on silica gel (230-
400 mesh). Thin-layer chromatography (TLC) was performed using Silicycle SiliaplateTM glass 
backed plates (250 µm thickness, 60 Å porosity, F-254 indicator) and visualized using UV (254 
nm) or CAM, p-anisaldehyde, or KMnO4 stain. Unless otherwise indicated, 
1H, 13C, and DEPT-
135 NMR, COSY 45, HMQC, and NOESY spectra were acquired using DMSO-d6 or CDCl3 as 
solvent at room temperature. Chemical shifts are quoted in parts per million (ppm).  
 
3.4.1 General Procedure A: Synthesis of 1,3-azadienes 
To a round-bottom flask equipped with a stir bar was added the enal (10 mmol), amine (1 
to 1.5 equiv), benzene (50 mL), and anhydrous MgSO4 (2 g). The cloudy suspension was 
allowed to stir at room temperature. After complete consumption of the amine (based on TLC 
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monitoring), the mixture was filtered through and concentrated under reduced pressure to obtain 
the crude enamine, which was used in the next step without further purification. 
Note: The azadienes need to be stored in the refrigerator when not used immediately. 
 
3.4.2 General Procedure B: Reaction of 1, 3-azadienes with cyclic anhydrides 
A 5 mL screw-cap vial was flame-dried, evacuated and flushed with nitrogen. A solution 
of the 1,3-azadiene (1.0 mL, 0.10 M in freshly distilled toluene) was added to the vial at room 
temperature followed by the cyclic anhydride (1 to 1.1 equiv). The contents were placed in a pre-
heated oil bath thermostatted at the desired temperature (e.g., 90 oC for diglycolic anhydride). 
After complete consumption of the enal (as judged by TLC and NMR), the mixture/suspension 
was cooled to room temperature and washed several times with petroleum ether, then 
concentrated under reduced pressure to afford the crude cycloadducts. 
 
3.4.3 General Procedure C: Methyl esterification of cycloadducts 
To a stirring suspension of the acid (1 mmol), dissolved in DMF (5 mL), and K2CO3 (6 
equiv) was added methyl iodide (3 equiv) under nitrogen atmosphere. The reaction mixture was 
stirred for 12 to 18 h (TLC monitoring). After complete conversion, it was diluted with water and 
extracted with EtOAc (2×20 mL). The combined organic extracts were washed with brine, dried 
over Na2SO4 and concentrated in vacuo to give the desired ester. 
 
3.5 Peak Assignments 
3.5.1 Peak assignment for 17a 
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Prepared using General Procedure B then C in 1 mmol scale. In a vial with 2ml of dry 
toluene, 132mg of cyclic anhydride 15 and 237mg of 1, 3-aza-deine 17 were combined. 
Temperature= 90oC mineral oil bath for 18 hours. The reaction was cooled to room temperature 
and dissolved in 10ml of THF. 414mg (3 equiv) of K2CO3 and 0.12ml (2 equiv) of methyl iodide 
were added temp= room temp, time=overnight. After work up, the reaction was purified by flash 
chromatography on silica and eluted with hexane/EtOAc (80:20). Yield: 314.15mg, 82%. 
C21H21NO4S, MW: 383.12g/mol. 
1H NMR (400 MHz, Chloroform-d) δ 9.28 (s, 1H), 7.84 (d, J = 
11.0 Hz, 1H), 7.56 – 7.45 (m, 5H), 7.41 – 7.30 (m, 2H), 7.05 (d, J = 15.6 Hz, 1H), 6.91 – 6.72 (d, 
2H), 3.83 (s, 3H), 3.74 (s, 3H), 3.62 (s, 1H), 3.60 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 166.77, 
166.54, 156.36, 149.09, 144.00, 135.82, 131.34, 129.90, 128.99, 127.84, 124.50, 121.46, 114.13, 
114.08, 55.49, 53.09, 39.86. 
 
3.5.2 Peak assignment for 17b 
 
Prepared using General Procedure B then C in 1 mmol scale. In a vial with 2ml of dry 
toluene, 132mg of cyclic anhydride 15 and 237mg of 1, 3-aza-deine 17 were combined. 
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Temperature= 90oC mineral oil bath for 18 hours. The reaction was cooled to room temperature 
and dissolved in 10ml of THF. 414mg (3 equiv) of K2CO3 and 0.12ml (2 equiv) of methyl iodide 
were added temp= room temp, time=overnight. After work up, the reaction was purified by flash 
chromatography on silica and eluted with hexane/EtOAc (80:20). Yield: (313.9mg, 76%). 
C22H23NO5S, MW: 413.13g/mol. 
1H NMR (400 MHz, Chloroform-d) δ 9.31 (s, 1H), 7.89 – 7.79 
(m, 1H), 7.56 – 7.40 (m, 4H), 7.00 (d, J = 15.5 Hz, 1H), 6.95 – 6.70 (m, 4H), 3.89 – 3.60 (m, 
10H), 3.57 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 166.73, 161.19, 156.37, 149.97, 144.13, 
131.32, 129.55, 128.62, 122.35, 122.33, 121.63, 121.51, 114.48, 114.21, 114.16, 114.15, 114.12, 
114.08, 114.03, 55.50, 55.46, 53.00, 40.01. 
 
3.5.3 Peak assignment for 17c 
 
Prepared using General Procedure B then C in 3 mmol scale, 1 to 1 equiv. In a vial with 
2ml of dry toluene, 396mg of cyclic anhydride 15 and 885.4mg  of 1, 3-aza-deine 17 were 
combined. Temperature= 90oC mineral oil bath for 18 hours. The reaction was cooled to room 
temperature and dissolved in 10ml of THF. 1242mg (3 equiv) of K2CO3 and 0.37ml (2 equiv) of 
methyl iodide were added temp= room temp, time=overnight. After work up, the reaction was 
purified by flash chromatography on silica and eluted with hexane/EtOAc (90:10). Yield: 
(1.3234g, 3mmol) yield (1.045g, 79%) C23H23NO6S, MW: 441.12g/mol. 
1H NMR (400 MHz, 
Chloroform-d) δ 9.13 (s, 1H), 7.84 (dd, J = 11.1, 0.8 Hz, 1H), 7.56 – 7.39 (m, 2H), 7.20 – 6.97 
(m, 4H), 6.96 – 6.82 (m, 2H), 3.90 (s, 3H), 3.87 (m, 4H), 3.79 (s, 3H), 3.60 (s, 2H), 2.35 (s, 3H). 
60 
 
13C NMR (101 MHz, CDCl3) δ 168.89, 166.75, 166.31, 156.47, 151.53, 148.83, 143.35, 141.21, 
134.79, 131.17, 124.60, 123.37, 121.41, 120.92, 114.15, 111.05, 53.16, 39.96, 20.75. FTIR 
(KBr): 3307.5463, 2951.8727, 1764.2599, 1707.5906, 1678.7966, 1601.0784, 1539.9008, 
1511.2657, 1464.3966, 1435.3527, 1414.9622, 1369.561, 1286.5374, 1268.5559, 1246.0587, 
1197.2471, 1154.7993, 1121.5752, 1033.6386, 978.8318, 907.1187, 829.2555 
 
3.5.4 Peak assignment for 17d 
 
Prepared using General Procedure B then C in 1 mmol scale. In a vial with 2ml of dry 
toluene, 132mg of cyclic anhydride 15 and 282mg of 1, 3-aza-deine 17 were combined. 
Temperature= 90oC mineral oil bath for 18 hours. The reaction was cooled to room temperature 
and dissolved in 10ml of THF. 414mg (3 equiv) of K2CO3 and 0.12ml (2 equiv) of methyl iodide 
were added temp= room temp, time=overnight. After work up, the reaction was purified by flash 
chromatography on silica and eluted with hexane/EtOAc (90:10). Yield: 381.0mg, 89%. 
C21H20N2O6S, MW: 428.10g/mol.  
1H NMR (400 MHz, DMSO-d6) δ 10.00 (s, 1H), 8.26 – 8.14 
(d, 2H), 7.76 (d, J = 10.9 Hz, 1H), 7.73 – 7.66 (m, 2H), 7.58 – 7.32 (m, 3H), 6.79 – 6.70 (d, 10.9 
Hz, 2H), 3.63 (s, 3H), 3.59 (s, 3H), 3.52 (s, 1H), 3.35 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 
166.55, 165.54, 155.74, 147.59, 146.58, 142.86, 139.85, 132.49, 129.21, 128.71, 127.89, 124.53, 
121.10, 114.21, 55.54, 53.20, 38.55. FTIR: 3305.8555, 2950.6886, 1710.3697, 1660.5034, 
1595.7104, 1510.7871, 1462.8195, 1434.7756, 1412.6496, 1340.5359, 1301.1867, 1270.7815, 
1234.8995, 1179.9898, 1109.4592, 1034.1616, 976.2637, 915.214, 865.5132 
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3.5.5 Peak assignment for 17e 
 
Prepared using General Procedure B then C in 1 mmol scale. In a vial with 2ml of dry 
toluene, 132mg of cyclic anhydride 15 and 275mg of 1, 3-aza-deine 17 were combined. 
Temperature= 90oC mineral oil bath for 18 hours. The reaction was cooled to room temperature 
and dissolved in 10ml of THF. 414mg (3 equiv) of K2CO3 and 0.12ml (2 equiv) of methyl iodide 
were added temp= room temp, time=overnight. After work up, the reaction was purified by flash 
chromatography on silica and eluted with hexane/EtOAc (90:10). Yield: 366.4mg, 87%. 
C21H18F3NO3S, MW: 421.10g/mol. 
1H NMR (400 MHz, Chloroform-d) δ 9.80 (s, 1H), 7.96 (s, 
1H), 7.82 (dd, J = 13.1, 9.4 Hz, 2H), 7.55 – 7.31 (m, 7H), 7.02 (d, J = 15.7 Hz, 1H), 3.82 (s, 3H), 
3.76 (s, 1H), 3.60 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 167.53, 167.05, 149.66, 144.43, 
138.78, 135.70, 130.01, 129.49, 128.98, 127.86, 124.35, 123.86, 122.90, 120.78, 120.74, 116.46, 
116.42, 53.11, 40.09. 
 
3.5.6 Peak assignment for 17f 
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Prepared using General Procedure B then C in 2 mmol scale, 1 to 1 equiv. In a vial with 
2ml of dry toluene, 246mg of cyclic anhydride 15 and 474mg of 1, 3-aza-deine 17 were 
combined. Temperature= 90oC mineral oil bath for 18 hours. The reaction was cooled to room 
temperature and dissolved in 10ml of THF. 828mg (3 equiv) of K2CO3 and 0.24ml (2 equiv) of 
methyl iodide were added temp= room temp, time=overnight. After work up, the reaction was 
purified by flash chromatography on silica and eluted with hexane/EtOAc (80:20). Yield: 
613.0mg, 80%. C21H21NO4S, MW: 383.12g/mol. 
1H NMR (400 MHz, Chloroform-d) δ 9.34 (s, 
1H), 7.87 (d, J = 11.1 Hz, 2H), 7.59 – 7.45 (m, 2H), 7.37 – 7.23 (m, 4H), 7.27 – 7.16 (m, 3H), 
6.65 – 6.63 (m, 1H), 3.55 – 3.71 (m, 7H), 3.62 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 166.83, 
166.65, 160.17, 149.18, 144.32, 139.23, 135.76, 130.03, 129.68, 129.04, 127.88, 124.35, 111.95, 
110.40, 105.24, 55.31, 53.17, 40.17. FTIR: 3318.3107, 2949.3476, 1708.1158, 1685.4836, 
1608.3796, 1577.3754, 1546.7655, 1492.8552, 1453.3282, 1432.6108, 1266.33, 1226.4322, 
1158.0539, 1044.6317, 976.2533, 854.0879, 774.972, 749.531, 690.3492 
 
3.5.7 Peak assignment for 17g 
 
Prepared using General Procedure B then C in 2 mmol scale, 1 to 1 equiv. In a vial with 
2ml of dry toluene, 246mg of cyclic anhydride 15 and 474mg of 1, 3-aza-deine 17 were 
combined. Temperature= 90oC mineral oil bath for 18 hours. The reaction was cooled to room 
temperature and dissolved in 10ml of THF. 828mg (3 equiv) of K2CO3 and 0.24ml (2 equiv) of 
methyl iodide were added temp= room temp, time=overnight. After work up, the reaction was 
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purified by flash chromatography on silica and eluted with hexane/EtOAc (80:20). Yield: 
(536.4mg, 70%). C21H21NO4S, MW: 383.12g/mol. 
1H NMR (400 MHz, Chloroform-d) δ 8.86 (s, 
1H), 8.34 (dd, J = 8.0, 1.7 Hz, 1H), 7.81 (d, J = 11.2 Hz, 1H), 7.60 – 7.49 (m, 2H), 7.50 (d, J = 
1.6 Hz, 1H), 7.46 – 7.29 (m, 2H), 7.12 – 6.98 (m, 2H), 6.93 (td, J = 7.8, 1.4 Hz, 1H), 6.84 (dd, J 
= 8.1, 1.4 Hz, 1H), 3.95 – 3.80 (m, 9H). 13C NMR (101 MHz, CDCl3) δ 166.36, 165.82, 147.74, 
143.06, 136.05, 129.64, 128.92, 127.72, 124.57, 124.06, 121.10, 119.82, 110.08, 55.83, 52.83, 
39.25. 
 
3.5.8 Peak assignment for 17h 
 
Prepared using General Procedure B then C in 1 mmol scale. In a vial with 2ml of dry 
toluene, 132mg of cyclic anhydride 15 and 237mg of 1, 3-aza-deine 17 were combined. 
Temperature= 90oC mineral oil bath for 18 hours. The reaction was cooled to room temperature 
and dissolved in 10ml of THF. 414mg (3 equiv) of K2CO3 and 0.12ml (2 equiv) of methyl iodide 
were added temp= room temp, time=overnight. After work up, the reaction was purified by flash 
chromatography on silica and eluted with hexane/EtOAc (75:25). Yield: 307.2mg, 84%. 
C20H19NO3S, MW: 353.11g/mol. 
1H NMR (400 MHz, Chloroform-d) δ 9.38 (s, 1H), 7.84 (d, J = 
11.1 Hz, 1H), 7.64 – 7.28 (m, 9H), 7.15 – 6.95 (m, 2H), 3.83 (s, 3H), 3.76 – 3.62 (m, 3H). 13C 
NMR (101 MHz, CDCl3) δ 166.93, 166.86, 149.23, 144.26, 129.99, 129.02, 128.99, 127.88, 
124.43, 124.41, 119.83, 53.15, 40.07. 
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3.5.9 Peak assignment for 17i 
 
Prepared using General Procedure B then C in 1 mmol scale. In a vial with 2ml of dry 
toluene, 132mg of cyclic anhydride 15 and 237mg of 1, 3-aza-deine 17 were combined. 
Temperature= 90oC mineral oil bath for 18 hours. The reaction was cooled to room temperature 
and dissolved in 10ml of THF. 414mg (3 equiv) of K2CO3 and 0.12ml (2 equiv) of methyl iodide 
were added temp= room temp, time=overnight. After work up, the reaction was purified by flash 
chromatography on silica and eluted with hexane/EtOAc (70:30). Yield: 572.7mg, 78%. 
C21H21NO3S, MW: 367.12g/mol. 
1H NMR (400 MHz, Chloroform-d) δ 9.28 (s, 1H), 7.86 (d, J = 
11.1 Hz, 1H), 7.60 – 7.42 (m, 5H), 7.45 – 7.29 (m, 2H), 7.17 – 7.02 (m, 3H), 3.85 – 3.79 (m, 
4H), 3.61 (s, 2H), 2.30 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 166.67, 149.16, 144.12, 135.82, 
135.55, 133.93, 129.94, 129.49, 129.01, 127.88, 124.46, 119.85, 53.11, 39.98, 20.98. FTIR: 
3305.6305, 1708.2795, 1684.3838, 1659.5195, 1607.6156, 1577.1249, 1533.7109, 1513.7441, 
1447.6363, 1433.8469, 1405.1485, 1320.1294, 1301.793, 1266.6822, 1228.5506, 1179.779, 
1161.7804, 1043.5251, 976.6377 
 
3.5.10 Peak assignment for 17j 
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Prepared using General Procedure B then C in 1 mmol scale. In a vial with 2ml of dry 
toluene, 132mg of cyclic anhydride 15 and 237mg of 1, 3-aza-deine 17 were combined. 
Temperature= 90oC mineral oil bath for 18 hours. The reaction was cooled to room temperature 
and dissolved in 10ml of THF. 414mg (3 equiv) of K2CO3 and 0.12ml (2 equiv) of methyl iodide 
were added temp= room temp, time=overnight. After work up, the reaction was purified by flash 
chromatography on silica and eluted with hexane/EtOAc (80:20). Yield: 380.0mg, 81%. 
 C20H18INO3S, MW: 479.01g/mol. 
1H NMR (400 MHz, Chloroform-d) δ 9.54 (s, 1H), 7.85 (d, J 
= 11.1 Hz, 1H), 7.76 – 7.35 (m, 9H), 7.09 (d, J = 15.4 Hz, 1H), 3.85 (s, 3H), 3.56 (s, 3H), 3.34 
(dd, J = 24.2, 14.1 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 167.07, 166.85, 149.54, 144.53, 
137.94, 137.88, 135.70, 130.12, 129.06, 127.90, 124.34, 121.56, 87.54, 53.24, 40.32. 
 
3.5.11 Peak assignment for 17k 
 
Prepared using General Procedure B then C in 1 mmol scale. In a vial with 2ml of dry 
toluene, 132mg of cyclic anhydride 15 and 237mg of 1, 3-aza-deine 17 were combined. 
Temperature= 90oC mineral oil bath for 18 hours. The reaction was cooled to room temperature 
and dissolved in 10ml of THF. 414mg (3 equiv) of K2CO3 and 0.12ml (2 equiv) of methyl iodide 
were added temp= room temp, time=overnight. After work up, the reaction was purified by flash 
chromatography on silica and eluted with hexane/EtOAc (80:20). Yield: 362.7mg, 79%. 
C27H25NO4S, MW: 459.15g/mol. 
1H NMR (400 MHz, DMSO-d6) δ 10.03 (s, 1H), 7.63 – 7.21 
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(m, 9H), 7.24 – 7.10 (m, 4H), 6.99 – 6.80 (m, 2H), 3.72 – 3.61 (m, 7H), 3.37 (s, 2H). 13C NMR 
(101 MHz, DMSO) δ 166.79, 165.77, 155.83, 152.32, 145.15, 141.19, 138.72, 132.66, 130.57, 
129.20, 129.04, 129.01, 128.44, 126.22, 124.38, 121.20, 114.34, 55.66, 53.04, 38.66. FTIR: 
3306.7102, 2949.6493, 1708.6269, 1659.3595, 1599.7096, 1572.3366, 1542.7743, 1510.163, 
1442.5061, 1412.5348, 1386.9519, 1246.5187, 1232.4069, 1178.0986, 1135.8322, 1036.1302, 
830.0752, 767.1022, 700.7011 
 
 
  
67 
 
CHAPTER IV 
Tandem Annulation and Amine-assisted Hydroalkylation of Allylic Alpha-chloro 
dehydrothiomorpholinates 
4.1 Introduction 
Sulfur-containing organic compounds are highly prevalent in natural and various 
biological systems.66–68,79 Drug discovery programs highly seek after the divalent sulfur atom 
due to its at ease metabolism.69 Indeed, it is worth noting that all the top ten best-selling drugs in 
2012 contained sulfur.70 In particular, sulfur-containing 1,4-heterocycles are ubiquitous 
pharmacophores often found in biologically active natural products as well as in synthetic drug 
molecules. For example, the 1,4-thiomorpholine moiety has been widely encountered in a variety 
of bioactive products, including DPP IV inhibitors, anti-inflammatory drugs, antimycobacterial 
agents, and hypolipidemic compounds.  
The biological relevance of sulfur-bearing motifs and their architectural complexity make 
them extremely important to the medicinal and synthesis communities. This, has prompted 
increase in the development of more flexible, efficient and cost-effective strategies to construct 
organo-sulfur motifs with peripheral functionalization. As well as the subsequent evaluation of 
structure-activity relationships of the biological activity of those compounds (i.e., S.A.R.).43  
Implementing multicomponent domino/cascade reactions is one way to reduce cost, 
given that they are inherently step and atom-economical. Additionally, in a diversity-oriented 
synthesis approach, complex generating cascade reactions offer an excellent platform to rapidly 
assembly complex compounds, which helps meet the demands of high-throughput screening for 
drug research and development.80 Domino processes often lead to an improvement in practicality 
due to the operationally simple experimental procedures and shorter reaction times as well as 
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decreased need for the isolation and purification of intermediates. Accordingly, the Beng group 
and those of Cushman,81 Shaw,82–84 Krasavin,37,85,86 Cronin,87 and Haimova88 have recognized 
the merits of the Castagnoli-Cushman reaction (i.e., the use of commodity chemicals such as 
amines, aldehydes and cyclic anhydrides, in a three-component reaction, to readily access 
nonflattened sp3-enriched core structures bearing vicinal stereocenters) and have continued to 
exploit this mode of reactivity. For example, we recently disclosed that through careful 
mitigation of the α-CH acidity of Krasavin-inspired cyclic anhydrides of type 1 (Fig 4-1A), and 
through rational design of inherently promiscuous 1,3-azadienes such as 2,89 an ideal balance of 
reactivity and selectivity is attainable, leading to cycloadducts of type 3.44  
 
 
Figure 4-1: Proposed plan for accessing vinylated dihydro-1,4-thiazines 
  
Accessing these vinylated dihydro-1,4-thiazines was desired. Upon recognizing that they 
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retain latent functionality throughout the periphery of the heterocycles which could be further 
manipulated. For example, as we have previously demonstrated on the piperidine90–92 and 
azepane90,93,94 heterocycles, the α-halo enamide/enamine motif could serve as a partner group for 
cross-couplings (see 5). Furthermore, the enal subunit may be engaged in conventional 1,2- and 
1,4-addition of carbon nucleophiles or in Deslongchamps-style annulations.95 Additionally, the 
styrenyl motif resident in 4 could pave the way for harnessing several reactivity modes, 
including hydroarylation,96 oxoamination,97 dioxygenation,98 dihydropyranation100 and boration. 
It was however recognized that successful implementation of the planned strategy would hinge 
on our ability to negate ring-opening events that are typically associated with thiomorpholines 
under strongly acidic or basic conditions, as well as to achieve site-selective Vilsmeier-Haack 
functionalization. At first glance, the latter objective has the makings of a wild goose chase given 
that the Vilsmeier-Haack reaction is notoriously promiscuous from the standpoint of 
chemoselectivity101 and impacts functionality such as electron-rich arenes, alkenes, esters and 
lactams. Herein, detailed efforts toward the construction of a diverse library of fully substituted 
vinylated and arylated dihydro-1,4-thiazines are described. The current work stands as an 
advance over existing methodologies given that the construction of these synthetically attractive 
architectures is achieved in highly modular and scalable fashions, and under mild conditions. 
Moreover, the synthetic intermediates are amenable to further functionalization featuring C-C 
and C-N bond forming events. 
 
4.2 Results and Discussion 
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The preferential reaction of a chemical reagent with one of two or more different 
functional groups (i.e., chemoselective functionalization) allows bond construction with 
increased synthetic efficiency since it obviates the need for functional group protection and/or 
oxidation adjustment. In this context, we initiated studies towards the construction of a diverse 
library of dihydro-1,4-thiazines by attempting to find mild and general chemoselective 
Vilsmeier-Haack conditions for preparing common precursor 4. At first glance, this has the 
makings of an impossible task given that the Vilsmeier-Haack reaction is notoriously 
promiscuous from the standpoint of chemoselectivity101 and impacts functionality such as 
electron-rich arenes, alkenes, alkynes, esters and lactams. Congruent with our initial findings,44 
we were pleased to find that under the reaction conditions described in Fig. 4-2, allylic 
thiomorpholinonates bearing N-alkyl, benzyl, and aryl substituents undergo lactam-selective 
functionalization. In most cases, high yields were obtained (see 4a‒h). The diastereomer ratios 
reflect those of the lactam precursors, indicating that undesirable epimerization did occur. It is 
noteworthy that this transformation tolerates diverse N-substituents given that such differential 
N-substitution has been shown to have profound effects on biological activity.102,103 The 
silica/Et3N system employed in these studies for hydrolysis of the intermediate chloromethylene 
iminium salts is optimal given that the use of conventional bases such as NaOH, KOH, NaOAc, 
or NH4OAc led to diminished yields and undesirable epimerization. 
Our studies have also revealed that thiomorpholinonates bearing α-amino benzylic 
stereocenters may also be converted to the corresponding chloroenals in high efficacy (see 4i‒o). 
A potentially beneficial aspect of this approach is the scalable nature of the reactions given that 
products such as 6a have been prepared in gram scale, without any compromise in efficiency. 
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Figure 4-2: Synthesis of allylic and benzylic dihydro-1,4-thiazines 
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Arguably, the power of any synthetic methodology lies in its ability to rapidly assemble 
molecularly complex in the most efficient manner possible. With this in mind, we have amply 
demonstrated that further manipulation of the chiral dihydro-1,4-thiazines prepared using the 
current strategy is possible. For example, a fully carbo-functionalized dihydro-1,4-thiazine is 
affordable when the halogen group resident in chloro enaminal 4h is utilized as a requisite group 
for one-pot Pd- and Cu-catalyzed Sonogashira cross-coupling with triisopropylsilylacetylene 
(Fig 4-3). It is notable that epimerization is not observed under these mild alkynylation 
conditions as judged by the observation that enaminyne 10 is obtained with complete 
stereofidelity. Importantly, it is relevant that sterically congested 4h couples prudently on the 
chloride terminus given that vinyl chlorides seldom feature in near room temperature cross-
couplings (presumably due to challenges associated with an extremely slow oxidative addition 
step104). 
 
Figure 4-3: Sonogashira cross-coupling of β-chloro-β-enaminals with a terminal alkyne 
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During the course of our studies on post-diversification of allylic 
dehydromorpholinonates such as 11, we uncovered that condensation of the α-alkoxy-β-chloro-
β-enaminals with primary aliphatic amines furnishes novel isolable and bench stable 1,4-diaza-2-
oxa-3-chloro-1,3-dienes such as 12 exclusively (Fig. 4-4).  
 
Figure 4-4: Synthesis of 1,4-diaza-1,3-dienes using β-chloroenal 12 
Encouraged by the isolable nature of 12, we sought to extend this mode of reactivity to 
allylic dehydrothiomorpholinonates. Our optimisim and desire was heightened by the recognition 
that the conversion of the aldehyde motif resident in 4 to imino dienes of type 13 (Fig 4-5) would 
greatly expand the 3D-structural space for the discovery of new sulfur-containing 
pharmaceuticals. Such an assertion stems from the knowledge that these imino dienes have the 
potential to serve as a reactive partner in annulation protocols such as Castagnoli-Cushman (see 
14),86 Tamura (see 15), Inverse-Electron Demand Diels-Alder (IEDDA) cycloadditions (see 16), 
intramolecular cross-coupling (see 17), triple amination (see 18), and Aza-Diels-Alder (ADA) 
cycloadditions105,106 (see 19). 
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Figure 4-5: Potential synthetic utility of β-chloro-imino dienes 
Intriguingly, treatment of a solution of chloro enaminal 4h in benzene with excess 
cyclopentylamine at room temperature in the presence of magnesium sulfate led to an 
unexpected amination at the vinyl chloride terminus followed by ring-opening (Fig 4-6). Support 
for the formation of 20a came from spectroscopic analysis. 
Figure 4-6. One-pot amination and deannulative hydroalkylation of β-chloro-β-enaminal 4a with 
cyclopentylamine 
Ring-opened product 20a contains several interesting structural features. It harbors motifs such 
as 1,1-enediamines, enethiols, β-enamino esters, and cross-conjugated-1,3-dienes. Highly labile 
enethiols bearing two β-amino substituents continue to garner interest from the medicinal 
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chemistry community.107–109 β-Enamino esters71,72 are well-recognized synthons for accessing 
azaheterocyclic architectures such as indoles, indolizidines, quinolines, pyrazoles, oxazoles, 
pyridinones, dihydropyridines, tetrahydrobenzoxazines, dibenzodiazepines, aminofuranones. 
This versatile motif has also been employed as a precursor to 3-aminosugar derivatives and β-
amino ketones. 1,1-Enediamines (i.e., ketene aminals or ketene N,N-acetals) whose generic 
structure is depicted in Fig 4-7, are a fascinating and versatile building block that is frequently 
used to assemble heterocyclic compounds, including quinolones, pyridinones, pyridines, 2-
pyranones, coumarins, dihydropyrazoles, pyrazoles, morphans, and β-substituted enamines.110–114 
These 1,1-enediamines (EDAMs) have the potential to serve as bis-nucleophiles (α-carbon and 
nitrogen as nucleophilic sites) and react with bis-electrophiles to furnish fused heterocyclic 
architectures.115N) in a tandem Michael/hetero-Michael sequence represents one of the most 
sagacious and step-economical approaches to the 2-azabicyclo [3.3.1] nonane scaffold,116 which 
is resident in pharmaceuticals and alkaloid natural products, including daphniphyllum alkaloids 
(e.g., longeracinphyllin B, cytotoxic agent117 ), opioid receptor antagonists (e.g., morphine118) 
and immunosuppressant FR9014834.119   
 
Figure 4-7: Generic structure of a 1,1-enediamine 
Encouraged by the potential utility of type 20, we moved to assemble a small library of 
these EDAMs (Fig 4-8). In the event, we find that various primary amines, including 
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cyclopentyl, cycloheptyl, cyclopropyl, benzyl, tert-butyl and allyl amines are tolerated. All were 
able to diastereoselectively and efficiently give tandem amination/hydroalkylation products 
without reacting with any of the other electrophilic sites in the molecule such as the aldehyde and 
ester. Strikingly, when excess isopropylamine was employed, stirring of a mixture of 4a and the 
former for three days furnishes a product of bis-amination at the vinyl chloride and enethiol 
termini (see 20e). Dihydro-1,1-thiazines bearing electron-rich styrenes as well as electron-
deficient styenes undergo this cascade amination-hydroalkylation reaction effortlessly. 
 
Figure 4-8: Deannulative hydroalkylation and amination of chloro-substituted allylic 
dehydrothiomorpholinonates 
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Enantioenriched EDAMs have been prepared using the current strategy by subjecting 
optically active Castagnoli-Cushman-derived allylic dehydrothiomorpholinonates to our 
optimized reaction conditions (Fig. 4-9).  
Figure 4-9: Deannulative hydroalkylation and amination of optically pure chloro-substituted 
allylic dehydrothiomorpholinonates 
 
Our unique approach to these EDAMs is characterized by its stereoselective, modular, 
cost-effective, atom-economical, and functional group-tolerant nature. Other indirect and lengthy 
approaches to EDAMs have been reported in the literature. Earlier synthetic approaches to 
ketene aminals was carried by the reaction of amines with ketene diethyl acetal, ortho-carbocylic 
ester and ketene O,N-acetal (Fig. 4-10A).120 The amine simultaneously displaces the acetal 
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groups. The symmetric nature of the synthesis was the major limitation as N-substituents lacked 
variation. New synthetic routes to 1,1-enediamines include the use of three component domino 
reactions featuring a thiocyanate, primary amine, and enolizable active methylene-bearing 
compounds (Fig. 4-10B).121 Copper-catalyzed cross-coupling of γ-lactams with dibromo styrenes 
using N,N-dimethylethylenediamine as a ligand has also been explored (Fig. 4-10C).122 
Additionally, propargyl amine-assisted amination of bromorpropiolates under basic conditions 
are known to furnish highly functionalized EDAMs (Fig. 4-10D).123 
 
Figure 4-10: Synthetic routes to 1,1-enediamines 
 
In yet another stunning outcome, our studies have revealed that treatment of N-aryl-
substituted chloro enaminal 4h with excess isopropylamine for three days at room temperature 
leads to two C-N bond forming reactions (Fig. 4-5). The expected imination reaction takes place 
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followed by an amination reaction at the vinyl chloride terminus (see 42). In this mode of 
reactivity, ring-opening is not observed, consistent with our early findings that internally 
trisubstituted styrenyl dehydrothiomorpholinonates are not susceptible to ring-opening. 
 
Figure 4-11: One-pot amination and imination of N-aryl-substituted-β-chloro-β-enaminal 4h 
with isopropylamine 
 
4.3 Conclusions 
 In summary, chemoselective Vilsmeier-Haack functionalization of densely populated 
allylic and benzylic thiomorpholinonates has been successfully implemented, leading to the 
diversity-oriented synthesis of vicinally functionalized and potentially bioactive dihydro-1,4-
thiazines. The synthetic utility of the methodology has been amply demonstrated through 
elaboration of the products to fully carbo-substituted dehydrothiomorpholines. The cascade 
diastereoselective amination and intramolecular amine-assisted hydroalkylations of allylic 
dehydrothiomorpholinonates has been developed. The current work stands as an advance over 
existing methodology given that the construction of these versatile intermediates can be achieved 
in scalable, step-economical, stereoselective, high-yielding, and transition metal-free fashions. 
The amenability of these highly functionalized intermediates to C‒C and C‒N bond forming 
80 
 
transformations bodes well for future late-stage assembly of complex thiomorpholine-bearing 
bioactive molecules and materials.  
 
4.4 Methods 
All experiments involving air and moisture-sensitive reagents were carried out under an 
inert atmosphere of nitrogen and using freshly distilled solvents. Freshly purchased DMF was 
stored under 4 Ao molecular sieves for several days prior to use. THF was distilled from sodium 
benzophenone ketyl. All amines and enals were newly purchased and used without further 
purification. Column chromatography was performed on silica gel (230-400 mesh). Thin-layer 
chromatography (TLC) was performed using Silicycle SiliaplateTM glass backed plates (250 µm 
thickness, 60 Å porosity, F-254 indicator) and visualized using UV (254 nm) or CAM, p-
anisaldehyde, or KMnO4 stain. All reported temperatures were internal to a reaction vessel. 
Unless otherwise indicated, 1H, 13C, and DEPT-135 spectra were acquired using CDCl3 as 
solvent, at room temperature. Chemical shifts are quoted in parts per million (ppm). HRMS-EI+ 
data were obtained using either electronspray ionization (ESI) or electron impact (EI) techniques. 
High-resolution ESI was obtained on an LTQ-FT (ion trap; analyzed using Excalibur). High 
resolution EI was obtained on an Autospec (magnetic sector; analyzed using MassLynx).  
Brine solutions are saturated solutions of aqueous sodium chloride. The lactam precursors 
utilized in these studies were prepared using our recently reported protocol,1 described below for 
purposes of completeness. 
 
Reaction of 1,3-azadienes with diglycolic anhydride: A 5 mL screw-cap vial was 
flame-dried, evacuated and flushed with nitrogen. A solution of the 1,3-azadiene (1.0 mL, 0.10 
M in freshly distilled toluene) was added to the vial at room temperature followed by the 
diglycolic anhydride (1 to 1.1 equiv). The contents were placed in a pre-heated oil bath 
thermostatted at 90 oC. After complete consumption of the enal (as judged by TLC and NMR), 
the mixture/suspension was cooled to room temperature and washed several times with 
petroleum ether, then concentrated under reduced pressure to afford the crude lactamoyl acid. 
Note: The maximum scale we have performed this cycloaddition is 5 mmol.  
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Methyl esterification of lactamoyl acid: To a stirring suspension of the acid (1 mmol), 
dissolved in DMF (5 mL), and K2CO3 (6 equiv) was added methyl iodide (3 equiv) under 
nitrogen atmosphere. The reaction mixture was stirred for 12 to 18 h (TLC monitoring). After 
complete conversion, it was diluted with water and extracted with EtOAc (2×20 mL). The 
combined organic extracts were washed with brine, dried over Na2SO4 and concentrated in vacuo 
to give the desired ester, which was purified by flash chromatography on silica, if necessary. 
 
4.4.1 General procedure A: Vilsmeier-Haack functionalization 
To a solution of DMF (4 mmol, 4 equiv) in CH2Cl2 (5 mL) at 0 
oC was added dropwise, 
phosphorus oxychloride (2 mmol, 2 equiv). The resulting pale yellow mixture was refluxed for 
60 min. A solution of the lactamoyl ester (1 mmol, 1 equiv) in CH2Cl2 (5 mL) was added slowly 
under reflux. After complete addition of the lactam, the mixture was cooled to room temperature 
and stirred for the indicated time period (TLC and LC-MS monitoring was used to follow the 
extent of the reaction). Upon completion, the mixture was poured into a large flask containing 
crushed ice. After stirring at rt for 60 min, the layers were separated (the majority of the product 
stays in the DCM layer). Powdered K2CO3 was added slowly to the aqueous layer and the flask 
was swirled after each addition (Caution: it bubbles vigorously). The addition/swirling was 
continued until persistent cloudiness was observed. The neutralized/slightly basic mixture was 
extracted two times with CH2Cl2. The combined organic layers (three in total, one before and 
two after addition of K2CO3) were washed with brine and dried over Na2SO4 for 30 min. The 
mixture was filtered and concentrated under reduced pressure to give the desired product as an 
oily salt. 
Note1: With N-tert-butyl- or isopropyl-bearing lactamoyl esters or with POBr3, the reaction was 
performed under refluxing conditions. 
Note 2: With allylic morpholinonates, the reactions were typically complete in a day at room 
temperature (Scheme 1). 
Note 3: With benzylic morpholinonates, the reactions were typically complete in two days at 
room temperature (Scheme 2). 
Note 4: With allylic/benzylic thiomorpholinonates, the reactions were typically complete after 6 
h at room temperature (Scheme 3). 
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Note 5: The same procedure is amenable to large scale preparation of the chloro enals as show-
cased through the synthesis of 4b1 in 10 mmol scale and 4b4 in 5 mmol scale. 
 
4.4.2 General Procedure B: imination of dihydro 1, 4-thiazines 
In 20mL vial, Vilsmeier-Haack dihydro1, 4-thiazine products (1mmol scale) were 
dissolved in benzene. 1 g Magnesium sulfate and three equivalents of the respective amine were 
added and the reaction was stirred at room temperature, overnight.  The magnesium sulfate was 
filtered off and the product was concentrated on the rotatory evaporator. 1H, 13C and dept 135 
NMR data were acquired. Flash column chromatography was done on any additional 
purification.  
 
4.4.3 General procedure C: Sonogashira cross coupling of dihydro 1, 4-thiazine 
To a new 20 mL vial equipped with a stir bar, was added the dihydro1, 4-thiazine (1 
mmol, 1.0 equiv) in DMF (5 mL). The desired alkyne (1.2 equiv) was added followed by 
addition of Et3N (0.7 mL, 5 mmol, 5 equiv). PdCl2(PPh3)2 (35 mg, 5 mol%) and CuI (9.5 mg, 5 
mol%) were added rapidly and concurrently. The mixture was then stirred at the 60-80oC for the 
desired length of time (as indicated by TLC and LC-MS). Upon completion, the mixture was 
diluted with CH2Cl2 and columned. Purification: Flash chromatography on silica eluting with 
hexanes then hexane/EtOAc (80:20). 
 
4.5 Peak listings  
4.5.1 Peak assignments for 4a  
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Prepared from using General procedure A. To pre-generated Vilsmeier-Haack reagent, 
lactam (957.4mg, 3 mmol) in DCM was added. Temp = room temperature, time = 22 h, 
Purification: Flash chromatography on silica (pretreated with 1% Et3N) eluting with 
hexane/EtOAc (80:20). Yield = 887mg, 81%. 83:17 dr. C18H20ClNO3S, MW: 365.0852 g/mol. 
1H NMR (400 MHz, Chloroform-d) δ 9.81 (s, 1H), 7.44 – 7.28 (m, 5H), 6.49 (dd, J = 32.9, 15.7 
Hz, 1H), 6.16 (dd, J = 15.8, 6.8 Hz, 1H), 4.94 (ddd, J = 6.9, 2.9, 1.1 Hz, 1H), 4.85 (p, J = 6.7 Hz, 
1H), 3.88 (dd, J = 2.8, 1.0 Hz, 1H), 3.71 (s, 3H), 1.42 – 1.16 (m, 6H). 13C NMR (101 MHz, 
CDCl3) δ 185.50, 185.04, 169.41, 142.36, 135.60, 133.81, 132.67, 128.81, 128.77, 128.66, 
128.53, 128.39, 126.87, 126.84, 126.39, 122.49, 102.48, 56.85, 56.37, 53.06, 52.89, 52.56, 47.89, 
44.58, 22.34, 21.32, 20.71, 19.59. 
4.5.2 Peak assignment for 4b 
 
 
Prepared from using General procedure A. To pre-generated Vilsmeier-Haack reagent, 
lactam (346.1mg, 1 mmol) in DCM was added. Temp = room temperature, time = 20 h, 
Purification: Flash chromatography on silica (pretreated with 1% Et3N) eluting with 
hexane/EtOAc (90:10). Yield =353 mg, 86%, 95:5 dr. C18H19ClN2O5S: 410.1 g/mol. 
1H NMR 
(400 MHz, Chloroform-d) δ 9.83 (d, J = 1.0 Hz, 1H), 8.23 – 8.09 (m, 2H), 7.56 – 7.42 (m, 2H), 
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6.57 (dd, J = 15.9, 1.2 Hz, 1H), 6.33 (dd, J = 15.9, 6.3 Hz, 1H), 5.02 (ddd, J = 6.4, 2.9, 1.3 Hz, 
1H), 4.88 (p, J = 6.7 Hz, 1H), 3.95 (dd, J = 2.8, 1.0 Hz, 1H), 3.72 (s, 3H), 1.44 – 1.20 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ 185.13, 169.09, 147.44, 142.13, 142.03, 130.93, 130.47, 127.51, 
124.08, 123.98, 102.82, 56.46, 53.03, 52.96, 44.21, 22.28, 20.71. 
 
4.5.3 Peak assignments for 4c 
 
 
 
Prepared from using General procedure A. To pre-generated Vilsmeier-Haack reagent, 
lactam (872.8mg, 2.5 mmol) in DCM was added. Temp = room temperature, time = 22 h, 
Purification: Flash chromatography on silica (pretreated with 1% Et3N) eluting with 
hexane/EtOAc (80:20). Yield = 760 mg, 77 %, 65:35 dr. C19H22ClNO4S, MW: 395.10 g/mol. 
1H 
NMR (400 MHz, Chloroform-d) δ 9.86 (s, 1H), 7.38 – 7.25 (m, 2H), 6.94 – 6.81 (m, 2H), 6.49 
(d, J = 15.8 Hz, 1H), 6.05 (dd, J = 15.8, 7.1 Hz, 1H), 4.95 – 4.79 (m, 2H), 3.87 (d, J = 2.7 Hz, 
1H), 3.82 (s, 3H), 3.74 (s, 3H), 1.33 (d, J = 6.8 Hz, 3H), 1.26 (d, J = 6.8 Hz, 3H). 13C NMR (101 
MHz, CDCl3) δ 185.13, 169.56, 159.98, 142.30, 132.17, 128.24, 128.12, 124.20, 114.18, 102.48, 
57.06, 55.42, 52.97, 52.89, 44.88, 22.42, 20.73. 
 
4.5.4 Peak assignments for 4d 
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Prepared from using General procedure A. To pre-generated Vilsmeier-Haack reagent, 
lactam (345.1 mg, 1 mmol) in DCM was added. Temp = room temperature, time = 22 h, 
Purification: Flash chromatography on silica (pretreated with 1% Et3N) eluting with 
hexane/EtOAc (70:30). Yield = 324mg, 83 %, 90:10 dr. C20H22ClNO3S, MW: 391.10 g/mol. 
1H 
NMR (400 MHz, Chloroform-d) δ 9.85 (s, 1H), 7.44 – 7.32 (m, 5H), 6.48 (dd, J = 15.8, 1.3 Hz, 
1H), 6.14 (dd, J = 15.8, 6.2 Hz, 1H), 5.00 – 4.78 (m, 2H), 3.98 – 3.87 (m, 1H), 3.75 (s, 3H), 1.99 
– 1.73 (m, 8H). 13C NMR (101 MHz, CDCl3) δ 185.12, 169.56, 132.68, 128.78, 128.56, 126.85, 
125.92, 102.93, 62.63, 57.27, 52.91, 44.25, 30.97, 29.40, 23.06, 23.04. 
 
4.5.5 Peak assignments for 4e 
 
Prepared from using General procedure A. To pre-generated Vilsmeier-Haack reagent, 
lactam (1906mg, 5 mmol) in DCM was added. Temp = room temperature, time = 22 h, 
Purification: Flash chromatography on silica (pretreated with 1% Et3N) eluting with 
hexane/EtOAc (80:20). Yield =1708mg, 80 %, 70:30 dr. C23H22ClNO3S, MW: 427.10 g/mol.  
1H NMR (400 MHz, Chloroform-d) δ 9.96 (s, 1H), 7.46 – 7.30 (m, 10H), 6.48 (dd, J = 15.8, 1.3 
Hz, 1H), 6.04 – 5.89 (m, 2H), 4.79 (ddd, J = 6.4, 2.8, 1.4 Hz, 1H), 3.66 (s, 3H), 2.93 (d, J = 2.8 
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Hz, 1H), 1.77 (d, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 185.86, 167.60, 140.99, 
137.01, 135.86, 133.72, 129.25, 128.68, 127.42, 126.89, 122.43, 58.56, 56.94, 53.05, 46.52, 
17.26. 
 
 
4.5.6 Peak assignments for 4f 
 
 
 
Prepared from using General procedure A. To pre-generated Vilsmeier-Haack reagent, 
lactam (2055mg, 5 mmol) in DCM was added. Temp = room temperature, time = 22 h, 
Purification: Flash chromatography on silica (pretreated with 1% Et3N) eluting with 
hexane/EtOAc (80:20). Yield =1737mg, 76%, 60:40 dr. C24H24ClNO4S, MW: 457.1115 g/mol. 
1H NMR (400 MHz, Chloroform-d) δ 9.95 (s, 1H), 7.52 – 7.25 (m, 6H), 7.02 – 6.81 (m, 3H), 
6.80 – 6.68 (m, 0H), 6.51 – 6.37 (m, 1H), 5.97 (dq, J = 21.1, 7.1 Hz, 1H), 5.89 – 5.73 (m, 1H), 
4.79 – 4.62 (m, 1H), 3.93 – 3.78 (m, 4H), 3.77 (s, 3H), 3.42 (s, 1H), 1.76 (d, J = 7.1 Hz, 3H). 13C 
NMR (101 MHz, CDCl3) δ 185.85, 167.61, 159.84, 137.07, 133.75, 133.19, 129.23, 128.85, 
128.64, 128.59, 128.56, 128.16, 128.05, 127.72, 127.42, 120.17, 114.16, 114.10, 114.06, 113.83, 
106.18, 77.45, 77.13, 76.82, 58.59, 57.14, 55.41, 53.01, 48.33, 46.69, 33.55, 17.29. FTIR: 
2953.1358, 1737.317, 1637.8394, 1606.9495, 1535.6511, 1511.6239, 1452.2459, 1437.5007, 
1403.8348, 1383.8483, 1354.3658, 1301.4903, 1248.8188, 1174.9602, 1121.0927, 1029.1901, 
965.1573, 828.5311, 701.7506. 
 
 
4.5.7 Peak assignments for 4g 
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Prepared from using General procedure A. To pre-generated Vilsmeier-Haack reagent, 
lactam (363 mg, 1 mmol) in DCM was added. Temp = room temperature, time = 22 h, 
Purification: Flash chromatography on silica (pretreated with 1% Et3N) eluting with 
hexane/EtOAc (80:20). Yield =331mg, 81%, 83:17 dr. C20H24ClNO4S, MW: 409.1115 g/mol. 
1H 
NMR (400 MHz, Chloroform-d) δ 9.80 (s, 1H), 7.31 (dd, J = 8.1, 6.8 Hz, 2H), 7.26 – 7.15 (m, 
3H), 6.23 (s, 1H), 4.96 (p, J = 6.7 Hz, 1H), 4.73 – 4.67 (m, 1H), 3.93 – 3.88 (m, 1H), 3.70 (s, 
3H), 1.91 (d, J = 1.3 Hz, 3H), 1.33 (d, J = 6.7 Hz, 3H), 1.24 (d, J = 6.6 Hz, 3H). 13C NMR (101 
MHz, CDCl3) δ 184.98, 169.58, 143.56, 136.66, 134.38, 128.99, 128.71, 128.28, 127.12, 101.62, 
62.07, 53.45, 52.88, 40.74, 21.54, 20.85, 15.75. 
 
 
4.5.8 Peak assignments for 4h 
 
 
Prepared using General Procedure A. Temp = room temperature, time = 6 h, Flash 
chromatography on silica (pretreated with 1% Et3N) eluting with hexane/EtOAc (80:20). Yield = 
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314 mg, 71%.
 1H NMR (400 MHz, Chloroform-d) δ 9.99 (s, 1H), 7.34 (m, 7H), 7.25 (d, J = 7.2 
Hz, 2H), 6.46 (s, 1H), 4.88 (d, 1H), 3.96 (d, J = 2.5 Hz, 1H), 3.83 (s, 3H), 3.72 (s, 3H), 1.91 (s, 
3H).
 13C NMR (101 MHz, CDCl3) δ 185.4, 170.4, 159.2, 142.6, 137.3, 136.5, 133.3, 131.5, 
129.5, 129.1, 129.1, 114.9, 102.5, 72.6, 55.5, 53.1, 40.1, 17.6. HRMS calc for C23H20ClNO4S, 
443.0958, found 443.0965. 
 
 
4.5.9 Peak assignments for 4i 
 
 
 
Prepared using General Procedure A. lactam (355mg, 1 mmol), POCl3 (0.31 g, 0.2 mL, 
2 mmol), DMF (0.33 mL, 4 mmol), Temp = room temperature, time = 6 h, Purification: Flash 
chromatography on silica (pretreated with 1% Et3N) eluting with hexane/EtOAc (50:50). Yield = 
317 mg, 82%.
 1H NMR (400 MHz, Chloroform-d) δ 9.84 (s, 1H), 7.31 – 7.02 (m, 10H), 5.25 (d, 
J = 16.0 Hz, 1H), 4.95 (s, 1H), 4.12 (d, J = 15.9 Hz, 1H), 3.44 (s, 3H), 2.23 (dd, J = 16.2, 5.6 Hz, 
1H). 13C NMR (400 MHz, CDCl3) δ 187.2, 171.7, 150.4, 139.1, 135.7, 129.2, 128.2, 127.5, 
126.9, 106.2, 63.6, 53.8, 51.8, 42.6. HRMS calc for C20H18ClNO3S, 387.0696, found 387.0691. 
 
4.5.10 Peak assignments for 4j  
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Prepared using General Procedure A. lactam (385mg, 1 mmol), POCl3 (0.31 g, 0.2 mL, 
2 mmol), DMF (0.33 mL, 4 mmol), Temp = room temperature, time = 6 h, Purification: Flash 
chromatography on silica (pretreated with 1% Et3N) eluting with hexane/EtOAc (50:50). Yield = 
300 mg, 72%, 95:5 dr. 1H NMR (400 MHz, Chloroform-d) δ 9.90 (s, 1H, 7.28 – 7.12 (m, 5H), 
6.90 – 6.72 (m, 3H), 5.27 (d, J = 16.1 Hz, 1H), 5.12 (d, J = 2.4 Hz, 1H), 4.35 (d, J = 16.1 Hz, 
1H), 3.75 – 3.58 (m, 7H). 13C NMR (101 MHz, CDCl3) δ 185.0, 167.1, 159.6, 145.15,  137.7, 
134.92, 130.06, 129.88, 129.55, 128.76, 128.43, 128.18, 127.98, 127.44, 127.01, 119.14, 114.49, 
113.77, 112.68, 102.23, 65.84, 56.50, 52.81, 44.03. HRMS calc for C21H20ClNO4S, 417.0802, 
found 417.0806. 
 
 
4.5.11 Peak assignments for 4k 
 
 
 
Prepared from using General procedure A. To pre-generated Vilsmeier-Haack reagent, 
lactam (293mg, 1 mmol) in DCM was added. Temp = room temperature, time = 10 h, 
Purification: Flash chromatography on silica (pretreated with 1% Et3N) eluting with 
hexane/EtOAc (80:20). Yield =254mg,75 %, 80:20 dr.1H NMR (400 MHz, Chloroform-d) δ 9.92 
(s, 1H), 7.44 – 7.22 (m, 3H), 7.19 – 7.12 (m, 2H), 5.36 (d, J = 2.5 Hz, 1H), 4.96 (p, J = 6.7 Hz, 
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1H), 3.89 – 3.83 (m, 4H), 1.31 (d, J = 6.8 Hz, 3H), 1.01 (d, J = 6.8 Hz, 3H). 13C NMR (101 
MHz, CDCl3) δ 184.98, 169.52, 140.98, 128.78, 128.46, 128.36, 127.20, 126.18, 100.89, 59.75, 
59.60, 53.80, 53.45, 52.86, 48.38, 43.91, 33.53, 22.35, 21.63, 20.68, 19.59. 
 
 
4.5.12 Peak assignments for 4l 
 
 
 
Prepared from using General procedure A. To pre-generated Vilsmeier-Haack reagent, 
lactam (323mg, 1 mmol) in DCM was added. Temp = room temperature, time = 20 h, 
Purification: Flash chromatography on silica (pretreated with 1% Et3N) eluting with 
hexane/EtOAc (80:20). Yield = 280mg, 76%, 80:20 dr. 1H NMR (400 MHz, Chloroform-d) δ 
9.85 (s, 1H), 7.06 (d, J = 8.2 Hz, 2H), 6.81 (d, J = 8.2 Hz, 2H), 5.29 (d, J = 2.7 Hz, 1H), 4.92 (p, 
J = 6.8 Hz, 1H), 3.74 – 3.69 (m, 7H), 1.28 (d, J = 6.7 Hz, 3H), 1.03 (d, J = 6.7 Hz, 3H). 13C 
NMR (101 MHz, CDCl3) δ 185.24, 184.91, 169.60, 159.48, 144.06, 133.10, 128.54, 127.44, 
114.09, 113.77, 100.76, 59.31, 59.15, 55.35, 55.23, 53.79, 53.44, 52.79, 48.49, 44.17, 22.37, 
21.67, 20.66, 19.60. 
 
 
4.5.13 Peak assignments for 4m  
 
91 
 
 
 
Prepared from using General procedure A. To pre-generated Vilsmeier-Haack reagent, 
lactam (307mg, 1 mmol) in DCM was added. Temp = room temperature, time = 19 h, 
Purification: Flash chromatography on silica (pretreated with 1% Et3N) eluting with 
hexane/EtOAc (80:20). Yield = 272mg, 77%, 95:5 dr.1H NMR (400 MHz, Chloroform-d) δ 
10.01 (s, 1H), 7.43 – 7.29 (m, 3H), 7.25 – 7.18 (m, 2H), 5.77 (d, J = 4.7 Hz, 1H), 3.97 (dd, J = 
4.7, 0.8 Hz, 1H), 3.76 (s, 3H), 1.61 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 185.70, 169.99, 
145.04, 139.43, 129.04, 128.29, 126.12, 63.41, 62.68, 52.98, 49.28, 31.49. 
 
 
4.5.14 Peak assignments for 4n 
 
 
 
 
Prepared using General Procedure A. lactam (337mg, 1 mmol), POCl3 (0.31 g, 0.2 mL, 2 
mmol), DMF (0.33 mL, 4 mmol), Temp = room temperature, time = 22 h, Purification: Flash 
chromatography on silica (pretreated with 1% Et3N) eluting with hexane/EtOAc (75:25). Yield = 
249 mg, 65%, 90:10 dr.1H NMR (400 MHz, Chloroform-d) δ 9.84 (s, 1H), 7.26 – 7.07 (m, 2H), 
6.86 – 6.71 (h, J = 7.5, 6.6 Hz, 2H)), 5.66 (d, J = 4.3 Hz, 1H), 3.95 – 3.85 (d, 1H), 3.79 –3.11 (d, 
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6H), 1.31 (d, 9H), 1.24 – 1.14 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 183.8, 170.8, 159.9, 
159.7, 144.6, 140.8, 130.0, 124.8, 118.7, 112.9, 112.0, 63.5, 61.9, 55.4, 53.1, 48.3, 32.9. HRMS 
calc for C18H22ClNO4S, 383.0958, found 383.0953. 
 
4.5.15 Peak assignments for 4o  
 
 
Prepared from using General procedure A. To pre-generated Vilsmeier-Haack reagent, 
lactam (291mg, 1 mmol) in DCM was added. Temp = room temperature, time = 18 h, 
Purification: Flash chromatography on silica (pretreated with 1% Et3N) eluting with 
hexane/EtOAc (80:20). Yield = 280 mg, 83%, 90:10 dr.1H NMR (400 MHz, Chloroform-d) δ 
9.88 (s, 1H), 7.45 – 7.27 (m, 3H), 7.23 – 7.09 (m, 2H), 5.39 (d, J = 3.0 Hz, 1H), 3.91 – 3.68 (m, 
1H), 3.72 (s, 3H), 3.06 (tt, J = 6.2, 4.6 Hz, 1H), 1.01 – 0.84 (m, 4H). 13C NMR (101 MHz, 
CDCl3) δ 184.71, 169.99, 146.43, 139.28, 129.01, 128.54, 126.00, 102.34, 67.09, 65.99, 52.89, 
43.41, 36.96, 10.02, 9.85. FTIR (KBr): 3011.0039, 2952.3396, 2856.8405, 1734.8848, 
1632.9162, 1586.0669, 1539.6415, 1496.1472, 1451.5135, 1434.9272, 1403.8612, 1355.2057, 
1315.3972, 1253.1437, 1217.5303, 1169.1404, 1070.1039, 1031.8757, 990.836, 970.3538, 
911.0351, 892.4749, 832.854, 805.3097, 769.7242, 751.5223 
 
4.5.16 Peak assignments for 10a 
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Prepared using General procedure C. dihydro 1, 4-thiazine (1 mmol, 1.0 equiv) in DMF 
(5 mL). triisopropylsilylacetylene (0.27 ml, 1.2 equiv) was added followed by addition of Et3N 
(0.7 mL, 5 mmol, 5 equiv). PdCl2(PPh3)2 (35 mg, 5 mol%) and CuI (9.5 mg, 5 mol%). The 
mixture was then stirred at the 40oC, 8 hours. The mixture was diluted with CH2Cl2 and 
columned. Purification: Flash chromatography on silica eluting with hexanes then hexane/EtOAc 
(80:20). Yield= 524mg, 89%, 95:5 dr.1H NMR (400 MHz, Chloroform-d) δ 9.97 (s, 1H), 7.45 – 
7.30 (m, 5H), 7.30 – 7.17 (m, 4H), 6.88 (d, 2H), 6.44 (s, 1H), 4.73 (t, J = 1.8 Hz, 1H), 3.96 (dd, J 
= 2.4, 1.0 Hz, 1H), 3.80 (s, 3H), 3.74 (s, 3H), 1.93 (s, 3H), 0.91 (s, 21H).
 13C NMR (101 MHz, 
CDCl3) δ 186.53, 169.89, 159.01, 139.01, 136.82, 134.42, 129.27, 129.09, 128.81, 128.70, 
128.63, 128.61, 128.31, 127.12, 114.21, 111.16, 105.21, 96.56, 67.61, 55.58, 52.86, 39.43, 18.63, 
18.53, 16.00, 11.03. 
 
4.5.17 Peak assignments for 10b 
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Prepared using General procedure C. dihydro 1, 4-thiazine (1 mmol, 1.0 equiv) in DMF 
(5 mL). triisopropylsilylacetylene (0.27 ml, 1.2 equiv) was added followed by addition of Et3N 
(0.7 mL, 5 mmol, 5 equiv). PdCl2(PPh3)2 (35 mg, 5 mol%) and CuI (9.5 mg, 5 mol%). The 
mixture was then stirred at the 40oC, 8 hours. The mixture was diluted with CH2Cl2 and 
columned. Purification: Flash chromatography on silica eluting with hexanes then hexane/EtOAc 
(80:20). Yield=529mg, 84%, 95:5 dr.1H NMR (400 MHz, Chloroform-d) δ 9.92 (s, 1H), 7.43 – 
7.20 (m, 7H), 6.57 (dd, J = 8.8, 4.0 Hz, 2H), 6.46 (s, 1H), 4.74 (t, J = 1.7 Hz, 1H), 3.97 – 3.91 
(m, 1H), 3.77 (s, 3H), 3.36 (q, J = 7.1 Hz, 4H), 1.98 (s, 3H), 1.22 – 1.05 (m, 6H), 0.93 (s, 21H). 
13C NMR (101 MHz, CDCl3) δ 186.41, 169.94, 147.14, 139.59, 137.04, 134.72, 134.21, 129.16, 
129.12, 128.27, 127.00, 111.28, 111.05, 110.07, 104.75, 96.73, 67.92, 52.81, 44.48, 39.45, 18.56, 
18.54, 16.07, 12.62, 11.10. 
 
 
4.5.18 Peak assignments for 42 
 
 
 
 
Prepared using general procedure B, dihydro1,4-thiazine 4h (1 mmol scale) dissolved in 
benzene (10 mL) and excess of isopropyl amine (1.0 mL) was added. Temp=room temperature, 
time=overnight. Filtered and concentrated on the rotatory evaporator. Yield= 524mg, 90%, 95: 5 
dr. 1H NMR (400 MHz, Chloroform-d) δ 8.20 (s, 1H), 7.37 – 7.26 (m, 2H), 7.28 – 7.19 (m, 2H), 
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7.23 – 7.05 (m, 1H), 7.05 – 6.97 (m, 2H), 6.93 – 6.78 (m, 2H), 6.64 (s, 1H), 5.35 (d, J = 1.5 Hz, 
1H), 4.68 (q, J = 1.5 Hz, 1H), 3.77 (s, 3H), 3.77 – 3.68 (m, 1H), 3.48 (s, 3H), 3.57 – 3.38 (m, 
2H), 2.01 (t, J = 1.1 Hz, 3H), 1.37 (d, J = 6.5 Hz, 6H), 1.33 – 1.18 (m, 6H). 13C NMR (101 MHz, 
CDCl3) δ 150.56, 129.52, 128.54, 127.69, 127.20, 124.97, 114.55, 73.09, 68.10, 62.32, 55.87, 
52.51, 44.60, 24.68, 24.63, 21.60, 16.13. 
 
4.5.19 Peak assignments for 20a  
 
Prepared using general procedure B, dihydro1,4-thiazine 4a (1 mmol scale) dissolved in 
benzene (10 mL) and three equivalents of cyclopentyl amine (0.3 mL) was added. Temp=room 
temperature, time=overnight. Filtered and concentrated on the rotatory evaporator. Yield= 
360mg, 87%. 1H NMR (400 MHz, Chloroform-d) δ 9.12 (s, 1H), 7.73 (dd, J = 15.5, 11.2 Hz, 
1H), 7.59 – 7.52 (m, 3H), 7.46 – 7.29 (m, 3H), 6.98 (d, J = 15.5 Hz, 1H), 4.02 – 3.67 (m, 2H), 
3.81 (s, 3H), 3.55 (s, 1H), 1.99 – 1.88 (m, 2H), 1.85 – 1.74 (m, 2H), 1.74 – 1.51 (m, 4H),  1.20 
(dd, 6H). 13C NMR (101 MHz, CDCl3) δ 186.35, 167.23, 162.34, 144.12, 141.74, 136.16, 
129.37, 128.92, 127.53, 124.38, 87.03, 56.05, 52.54, 46.21, 34.11, 23.70, 23.49. FTIR (KBr): 
3295.0934, 2960.3579, 2870.9399, 1702.5967, 1612.0676, 1584.8357, 1532.7346, 1448.3364, 
1433.9033, 1370.1122, 1295.7803, 1265.4695, 1224.6633, 1163.5073, 1127.0331, 1042.6731, 
975.7724, 749.2779 
 
4.5.20 Peak assignments for 20b 
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Prepared using general procedure B, dihydro1,4-thiazine 4a (1 mmol scale) dissolved in 
benzene (10 mL) and three equivalents of cycloheptyl amine was added (0.38 mL). Temp=room 
temperature, time=overnight. Filtered and concentrated on the rotatory evaporator. Yield= 
394mg, 89%. 1H NMR (400 MHz, Chloroform-d) δ 9.13 (s, 1H), 7.71 (dd, J = 15.5, 11.2 Hz, 
1H), 7.60 – 7.43 (m, 3H), 7.43 – 7.32 (m, 3H), 6.96 (d, J = 15.5 Hz, 1H), 3.78 (s, 3H), 3.77 – 
3.65 (m, 1H), 3.58 (tq, J = 8.6, 4.4 Hz, 1H), 1.95 (ddd, J = 13.9, 7.8, 3.7 Hz, 2H), 1.68 – 1.47 (m, 
10H), 1.33 – 1.10 (m, 6H). 13C NMR (101 MHz, CDCl3) δ 186.69, 167.23, 161.97, 143.95, 
141.67, 136.21, 129.37, 128.93, 127.55, 124.47, 87.14, 55.78, 52.56, 46.45, 35.41, 27.95, 23.75, 
23.45. FTIR (KBr): 1702.7484, 1610.5902, 1584.103, 1509.2225, 1447.4599, 1433.256, 
1370.5248, 1295.9273, 1265.0554, 1222.9586, 1162.5335, 1126.6568, 1073.2919, 1041.6161, 
974.9714, 911.2843, 807.3597, 748.7165 
 
4.5.21 Peak assignments for20c  
 
 
 
Prepared using general procedure B, dihydro1,4-thiazine 4b (1 mmol scale) dissolved in 
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benzene (10 mL) and three equivalents of cyclopropyl amine (0.2 mL) was added. Temp=room 
temperature, time=overnight. Filtered and concentrated on the rotatory evaporator. Yield= 
349mg, 81%. 1H NMR (400 MHz, Chloroform-d) δ 9.01 (s, 1H), 8.26 (d, 2H), 7.84 (dd, J = 15.6, 
11.1 Hz, 1H), 7.71 (d, 2H), 7.51 (dd, J = 13.2, 9.9 Hz, 1H), 6.97 (d, J = 15.6 Hz, 1H), 4.53 (dp, J 
= 8.9, 6.4 Hz, 1H), 3.81 (s, 3H), 3.79 – 3.73 (m, 1H), 2.74 (dh, J = 6.9, 3.6 Hz, 1H), 1.30 (d, J = 
6.4 Hz, 6H), 0.85 (ddq, J = 10.0, 3.7, 2.1 Hz, 4H). 13C NMR (101 MHz, CDCl3) δ 186.08, 
166.84, 163.45, 147.66, 142.50, 142.07, 138.04, 133.49, 128.51, 127.91, 124.28, 85.75, 52.78, 
45.90, 30.38, 23.85, 9.15. FTIR: 3292.3893, 2975.7823, 1705.3691, 1618.571, 1583.5179, 
1517.1585, 1453.5682, 1434.3452, 1367.527, 1339.9847, 1298.4332, 1269.0813, 1228.2995, 
1162.9778, 1126.5532, 1109.1746, 1038.9605 977.8593, 911.2805, 865.3065, 832.2572 
 
 
4.5.22 Peak assignments for 20d 
 
 
 
 
Prepared using general procedure B, dihydro1,4-thiazine 4a (1 mmol scale) dissolved in 
benzene (10 mL) and three equivalent of benzyl amine (0.32ml) was added. Temp=room 
temperature, time=overnight. Filtered and concentrated on the rotatory evaporator. Yield= 
401mg, 92%. 1H NMR (400 MHz, Chloroform-d) δ 9.18 (s, 1H), 7.68 (dd, J = 15.3, 11.1 Hz, 
1H), 7.60 – 7.22 (m, 11H), 6.92 (d, J = 15.5 Hz, 1H ), 4.52 (dd, J = 14.1, 5.9 Hz, 2H), 3.78 – 
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3.68 (m, 5H), 1.09 (m, 6H). 13C NMR (101 MHz, CDCl3) δ 187.07, 167.30, 164.03, 144.59, 
141.94, 137.40, 136.18, 129.41, 128.97, 128.94, 127.87, 127.62, 126.97, 124.40, 87.38, 52.61, 
49.16, 46.76, 23.74. FTIR: 3310.1978, 3028.1973, 2971.676, 1737.3676, 1703.2185, 1608.2729, 
1578.7167, 1535.2454, 1495.8743, 1449.7813, 1433.5873, 1368.4157, 1297.347, 1265.677, 
1225.0218, 1162.3421, 1076.4438, 1042.6683, 974.4603, 910.5392, 748.7441, 734.3327 
 
4.5.23 Peak assignments of 20e  
 
  
 
Prepared using general procedure B, dihydro1,4-thiazine 4a (1 mmol scale) dissolved in 
benzene (10 mL). 1 g Mg2SO4 and isopropyl amine (excess). Temp=room temperature, 
time=overnight. Filtered and concentrated on the rotatory evaporator. Yield= 355mg, 86%. 1H 
NMR (400 MHz, Chloroform-d) δ 9.09 (s, 1H), 7.69 (dd, J = 15.5, 11.1 Hz, 1H), 7.57 – 7.48 (m, 
3H), 7.34 (q, J = 7.7 Hz, 3H), 6.94 (d, J = 15.5 Hz, 1H), 3.76 (m, 6H), 3.50 (p, J = 6.7, 5.4 Hz, 
1H), 1.40 (d, J = 6.5 Hz, 6H), 1.24 (d, J = 6.4 Hz, 12H). 13C NMR (101 MHz, CDCl3) δ 186.48, 
167.21, 162.29, 144.23, 141.81, 136.15, 129.39, 128.94, 127.55, 124.39, 87.30, 52.57, 46.50, 
44.53, 23.38, 20.99. FTIR: 3292.478, 2973.8047, 2725.1511, 1703.6927, 1610.9728, 1585.1524, 
1524.2925, 1448.0139, 1433.735, 1369.9706, 1296.2306, 1265.8956, 1225.948, 1163.8338, 
1128.5918, 1042.657, 974.8688, 749.9101 
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4.5.24 Peak assignments of 20f  
 
 
Prepared using general procedure B, dihydro1,4-thiazine 4b (1 mmol scale) dissolved in 
benzene (10 mL) and three equivalents of allyl amine (0.22ml) was added. Temp=room 
temperature, time=overnight. Filtered and concentrated on the rotatory evaporator. Yield= 
367mg, 88%. 1H NMR (400 MHz, Chloroform-d) δ 9.18 (s, 1H), 8.26 (d, 2H), 7.80 (dd, J = 15.6, 
11.1 Hz, 1H), 7.71 (d, 2H), 7.46 (d, 1H), 6.94 (d, J = 15.6 Hz, 1H), 6.02 – 5.74 (m, 1H), 5.36 – 
5.00 (m, 2H), 4.00 – 3.87 (m, 2H), 3.76 (s, 3H), 1.29 (d, 6H). 13C NMR (101 MHz, CDCl3) δ 
186.53, 166.76, 163.69, 147.58, 142.50, 142.15, 138.09, 133.36, 133.32, 128.76, 128.47, 127.92, 
124.22, 123.93, 117.30, 86.52, 52.78, 47.43, 46.56, 23.71. FTIR: 2974.3243, 1705.6065, 
1622.1786, 1592.216, 1517.3388, 1434.3812, 1384.286,5 1341.4426, 1298.8313, 1269.0285, 
1226.7486, 1157.4256, 1126.4288, 1108.7724, 1040.0059, 864.5164, 746.5818 
 
 
4.5.25 Peak assignments for 20g  
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Prepared using general procedure B, dihydro1,4-thiazine 4a (1 mmol scale) dissolved in 
benzene (10 mL). 1 g Mg2SO4 and isopropyl amine (excess). Temp=room temperature, 
time=overnight. Filtered and concentrated on the rotatory evaporator. Yield= 390mg, 88%. 1H 
NMR (400 MHz, Chloroform-d) δ 9.09 (s, 1H), 7.62 – 7.41 (m, 4H), 6.96 – 6.78 (m, 3H), 3.80 
(s, 3H), 3.78 (s, 3H), 3.78 (dd, J = 4.9, 2.4 Hz, 1H), 3.77 – 3.64 (m, 4H), 3.50 (p, J = 6.5 Hz, 
1H), 1.36 – 1.20 (m, 18H). 13C NMR (101 MHz, CDCl3) δ 186.42, 167.41, 162.31, 160.75, 
145.27, 141.82, 129.14, 128.97, 127.95, 122.37, 114.41, 87.73, 55.41, 52.48, 46.49, 44.56, 23.37, 
20.95. FTIR (KBr): 3286.2028, 2974.1957, 2838.2028, 1700.901, 1625.476, 1600.0159, 
1575.6719, 1510.1201, 1462.6885, 1434.8049, 1369.7314, 1301.023, 1251.8596, 1228.4621, 
1174.1254, 1158.6669, 1129.4481, 1033.46, 823.082. 
 
 
4.5.26 Peak assignments for 23a 
 
 
 
Prepared using general procedure B, dihydro1,4-thiazine 4e (1 mmol scale) dissolved in 
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benzene (10 mL) and three equivalents of cycloheptryl amine (0.38ml) was added. Temp=room 
temperature, time=overnight. Filtered and concentrated on the rotatory evaporator. Yield= 
434mg, 86%.1H NMR (400 MHz, Chloroform-d) δ 9.19 (s, 1H), 7.74 (dd, J = 15.4, 11.1 Hz, 
1H), 7.58 (d, J = 11.1 Hz, 1H), 7.57 – 7.50 (m, 2H), 7.43 – 7.30 (m, 5H), 7.30 – 7.14 (m, 3H), 
6.98 (d, J = 15.5 Hz, 1H), 4.69 (p, J = 6.8 Hz, 1H), 3.78 (s, 3H), 3.79 – 3.70 (m, 1H), 3.59 – 3.37 
(m, 1H), 1.94 (ddt, J = 14.5, 7.7, 3.1 Hz, 1H), 1.73 – 1.33 (m, 14H). 13C NMR (101 MHz, 
CDCl3) δ 186.96, 167.29, 162.03, 144.23, 143.76, 141.83, 136.20, 129.40, 128.94, 128.91, 
127.57, 127.45, 125.37, 124.49, 87.18, 55.49, 55.13, 52.60, 35.74, 35.69, 27.66, 27.53, 25.93, 
23.76, 23.75. 
 
4.5.27 Peak assignments for 23b  
 
 
Prepared using general procedure B, dihydro1,4-thiazine 4e (1 mmol scale) dissolved in 
benzene (10 mL) and three equivalents of cyclopentyl amine (0.3ml) was added. Temp=room 
temperature, time=overnight. Filtered and concentrated on the rotatory evaporator. Yield= 
433mg, 91%. 1H NMR (400 MHz, Chloroform-d) δ 9.18 (s, 1H), 7.74 (dd, J = 15.4, 11.1 Hz, 
1H), 7.60 – 7.51 (m, 2H), 7.42 – 7.31 (m, 6H), 7.35 – 7.21 (m, 3H), 6.98 (d, J = 15.4 Hz, 1H), 
4.90 – 4.76 (m, 1H), 3.85 (dd, J = 12.7, 7.8 Hz, 1H), 3.77 (s, 3H), 3.80 – 3.72 (m, 1H), 1.88 
(ddd, J = 12.3, 6.5, 4.8 Hz, 1H), 1.70 (ddd, J = 8.7, 5.7, 3.3 Hz, 2H), 1.65 (d, J = 5.6 Hz, 1H), 
1.59 (d, J = 6.7 Hz, 3H), 1.49 – 1.37 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 186.84, 185.85, 
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167.34, 162.57, 144.30, 141.83, 136.21, 129.40, 128.95, 128.92, 128.89, 128.68, 127.58, 127.44, 
127.42, 126.89, 125.37, 124.44, 87.03, 55.92, 54.75, 52.58, 34.38, 34.17, 25.67, 23.68. 
 
 
4.5.28 Peak assignments for 23c 
 
 
 
Prepared using general procedure B, dihydro1,4-thiazine 4e (1 mmol scale) dissolved in 
benzene (10 mL) and three equivalents of isopropyl amine (0.23ml) was added. Temp=room 
temperature, time=overnight. Filtered and concentrated on the rotatory evaporator. Yield= 
392mg, 87%. 1H NMR (400 MHz, Chloroform-d) δ 9.21 (s, 1H), 7.74 (dd, J = 15.5, 11.1 Hz, 
1H), 7.58 (d, J = 11.1 Hz, 1H), 7.57 – 7.50 (m, 2H), 7.43 – 7.22 (m, 8H), 6.98 (d, J = 15.5 Hz, 
1H), 4.73 (p, J = 6.9 Hz, 1H), 3.77 (s, 3H), 3.70 (tdd, J = 12.7, 9.1, 7.1 Hz, 1H), 1.59 (d, J = 6.7 
Hz, 3H), 1.23 (d, J = 6.3 Hz, 3H), 0.98 (d, J = 6.3 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 
187.06, 167.30, 162.53, 144.42, 143.59, 141.89, 136.19, 129.67, 129.42, 128.96, 128.92, 127.59, 
127.48, 125.39, 125.34, 124.45, 87.32, 55.07, 52.58, 46.45, 25.72, 23.56, 23.38. 
 
 
4.5.29 Peak assignments for 23d 
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Prepared using general procedure B, dihydro1,4-thiazine 4e (1 mmol scale) dissolved in 
benzene (10 mL) and three equivalents of allyl amine (0.22ml) was added. Temp=room 
temperature, time=overnight. Filtered and concentrated on the rotatory evaporator. Yield= 
368mg, 82%. 1H NMR (400 MHz, Chloroform-d) δ 9.20 (s, 1H), 7.75 (dd, J = 15.4, 11.1 Hz, 
1H), 7.61 (d, J = 11.2 Hz, 1H), 7.54 (dd, J = 4.6, 2.4 Hz, 1H), 7.52 (d, J = 1.3 Hz, 1H), 7.37 – 
7.21 (m, 8H), 6.99 (d, J = 15.4 Hz, 1H), 5.81 (ddt, J = 17.2, 10.0, 4.8 Hz, 2H), 5.31 – 5.07 (m, 
4H), 4.84 – 4.72 (m, 1H), 3.77 – 3.58 (m, 7H), 1.56 (d, J = 6.7 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ 187.01, 167.42, 163.92, 145.15, 143.94, 142.17, 136.15, 133.72, 129.48, 128.96, 
128.82, 128.70, 127.64, 127.52, 125.33, 124.55, 117.13, 87.46, 54.67, 52.67, 47.20, 25.74. FTIR: 
2949.9629, 2927.1807, 1702.6746, 1611.8623, 1579.241, 1534.0703, 1493.7986, 1448.3892, 
1434.0474, 1374.9394, 1299.7635, 1266.7783, 1226.2658, 1153.973, 1042.0926, 988.4444, 
919.1959, 750.219 
 
 
4.5.30 Peak assignments for 23e 
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Prepared using general procedure B, dihydro1,4-thiazine 4f (1mmol scale) dissolved in 
benzene (10 mL) and three equivalents of cycloheptyl amine (0.38ml) was added. Temp=room 
temperature, time=overnight. Filtered and concentrated on the rotatory evaporator. Yield= 
476mg, 89%. 1H NMR (400 MHz, Chloroform-d) δ 9.21 (s, 1H), 7.67 – 7.55 (m, 2H), 7.55 – 
7.41 (m, 2H), 7.41 – 7.31 (m, 5H), 7.00 – 6.84 (m, 3H), 4.70 (h, J = 6.7 Hz, 1H), 3.81 (m, 7H), 
3.48 (ddq, J = 13.2, 8.9, 3.9 Hz, 1H), 1.94 (ddd, J = 13.8, 7.4, 3.5 Hz, 1H), 1.59 (d, J = 6.7 Hz, 
3H), 1.57 – 1.36 (m, 11H). 13C NMR (101 MHz, CDCl3) δ 186.95, 167.52, 162.08, 160.77, 
145.27, 143.82, 141.82, 129.16, 128.89, 127.42, 125.38, 122.50, 114.42, 87.59, 77.44, 77.13, 
76.81, 55.49, 55.45, 55.13, 52.53, 35.73, 35.69, 27.66, 27.52, 25.94, 23.78, 23.76. FTIR (KBr): 
1700.3298, 1599.1649, 1577.4965, 1509.3481, 1300.3655, 1250.9844, 1227.7848, 1173.823 
 
4.5.31 Peak assignments for 23f 
 
 
 
Prepared using general procedure B, dihydro1,4-thiazine 4f (1 mmol scale) dissolved in 
benzene (10 mL) and three equivalents of isopropyl amine (0.23ml) was added. Temp=room 
temperature, time=overnight. Filtered and concentrated on the rotatory evaporator. Yield= 
437mg, 91%. 1H NMR (400 MHz, Chloroform-d) δ 9.22 (s, 1H), 7.68 – 7.56 (m, 2H), 7.53 – 
7.45 (m, 2H), 7.39 – 7.30 (m, 2H), 7.26 (ddd, J = 6.9, 3.1, 1.4 Hz, 3H), 7.01 – 6.86 (m, 3H), 4.72 
(p, J = 6.8 Hz, 1H), 3.86 (s, 3H), 3.93 – 3.79 (m, 1H), 3.77 (s, 3H), 3.67 (dtd, J = 12.7, 6.4, 1.9 
Hz, 1H), 1.59 (d, J = 6.7 Hz, 3H), 1.31 – 1.20 (m, 4H), 0.98 (d, J = 6.3 Hz, 3H). 13C NMR (101 
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MHz, CDCl3) δ 187.05, 167.53, 162.58, 160.78, 145.43, 143.65, 141.87, 129.18, 128.90, 127.44, 
125.39, 122.48, 114.43, 87.73, 77.42, 77.10, 76.78, 55.45, 55.08, 52.51, 46.44, 25.73, 23.55, 
23.37. FTIR (KBr): 3293.9836, 2971.3809, 2837.3757, 1700.6526, 1599.2062, 1576.7616, 
1509.3376, 1451.3725, 1372.5259, 1300.2673, 1251.3073, 1228.9117, 1173.5301, 1156.6691, 
1127.5657, 1032.1314, 977.6689, 911.1765, 822.4428, 760.155, 730.9403 
4.5.32 Peak assignments for 23g 
 
 
 
Prepared using general procedure B, dihydro1,4-thiazine 4f  (1 mmol scale) dissolved in 
benzene (10 mL) and three equivalents of benzyl amine (0.32ml) was added. Temp=room 
temperature, time=overnight. Filtered and concentrated on the rotatory evaporator. Yield= 
502mg, 95%. 1H NMR (400 MHz, Chloroform-d) δ 9.26 (s, 1H), 7.59 (d, J = 13.5 Hz, 1H), 7.50 
– 7.43 (m, 2H), 7.41 – 7.25 (m, 6H), 7.29 – 7.18 (m, 2H), 7.22 – 7.15 (m, 2H), 7.16 (q, J = 2.0, 
1.2 Hz, 1H), 7.01 – 6.83 (m, 3H), 4.80 – 4.68 (m, 1H), 4.42 (dd, J = 15.3, 6.1 Hz, 1H), 4.34 (dd, 
J = 15.3, 6.2 Hz, 1H), 3.85 (s, 3H), 3.87 – 3.76 (m, 1H), 3.75 (s, 3H), 1.53 (d, J = 6.7 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 187.18, 167.63, 163.93, 160.82, 146.01, 143.95, 142.13, 137.62, 
129.25, 128.95, 128.89, 127.74, 127.51, 126.75, 125.37, 122.44, 114.42, 87.81, 55.46, 54.79, 
52.57, 48.68, 25.73. FTIR (KBr): 3307.6752, 3030.0248, 2950.6617, 2837.4792, 1702.347, 
1599.1031, 1575.267, 1509.7481, 1453.3663, 1435.2038, 1357.6909, 1301.3639, 1251.5765, 
1228.7266, 1174.2373, 1156.9306, 1110.757, 1030.1007, 978.0179, 823.0192 
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